STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
22507, Remsen 1d86

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

  Types of relevant prior art found:
  - ☐ Foreign Patent(s)
  - ☐ Non-Patent Literature
    (journal articles, conference proceedings, new product announcements etc.)
- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 08:56:23 ON 15 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JUN 2006  HIGHEST RN 887828-19-5
DICTIONARY FILE UPDATES:  14 JUN 2006  HIGHEST RN 887828-19-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from     *
* the IDE default display format and the ED field has been added,       *
* effective March 20, 2005.  A new display format, IDERL, is now        *
* available and contains the CA role and document type information.     *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d sta que 143
L25                 STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L27 1550 SEA FILE=REGISTRY SSS FUL L25
L28 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 19
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L30 14 SEA FILE=REGISTRY SUB=L27 SSS FUL L28
L31 STR



VAR G1=O/S/CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 19
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L33 985 SEA FILE=REGISTRY SUB=L27 SSS FUL L31
L37 STR





Page 2-A
VAR G1=H/AK/CY/30
VAR G2=AK/CY/30
VAR G3=H/AK/33/38/30/36
VAR G4=H/OH/61/57/45/49/53
VAR G5=H/OH/61/49
REP G6=(0-1) AK
VAR G7=H/AK/30/62/74/COOH/70
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 10
NUMBER OF NODES IS 64

STEREO ATTRIBUTES: NONE
L39 14 SEA FILE=REGISTRY SUB=L30 CSS FUL L37
L40 STR





Page 1-A



Page 2-A
VAR G1=H/AK/CY/30
VAR G2=AK/CY/30
VAR G3=H/AK/33/38/30/36
VAR G4=H/OH/61/57/45/49/53
VAR G5=H/AK/30/62/74/COOH/70
REP G6=(0-1) AK
VAR G7=O/S/CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 10
NUMBER OF NODES IS 64

```
STEREO ATTRIBUTES: NONE
L42          208 SEA FILE=REGISTRY SUB=L33 CSS FUL L40
L43          222 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L39 OR L42)


=> d his

     (FILE 'HOME' ENTERED AT 07:59:19 ON 15 JUN 2006)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 07:59:48 ON 15 JUN 2006
L1             1 S US20060052409/PN OR (US2005-520809# OR WO2003-JP8751 OR JP200
                 E TORAY/PA,CS
                 E KAWAI/AU
                 E KAWAI K/AU
L2           227 S E3,E4
                 E KAWAI KOJI/AU
L3           227 S E3-E6
                 E KAWAI NAME/AU
L4            22 S E4
                 E KOJI/AU
L5             1 S E39
L6             1 S E83
                 E SAITO/AU
L7           349 S E3-E6
L8            16 S E49,E50
                 E SAITO NAME/AU
L9           133 S E4
                 E AKIYOSHI/AU
L10            5 S E129
                 E SUZUKI/AU
L11           12 S E3
                 E SUZUKI T/AU
L12         3764 S E3-E9
                 E SUZUKI TOMOHIKO/AU
L13          145 S E3
                 E SUZUKI NAME/AU
L14          228 S E4
                 E TOMOHIKO/AU
L15            1 S E9
                 E HASEBE/AU
L16           38 S E57
L17          132 S E02
                 E HASEBE NAME/AU
                 E KO/AU
L18            2 S E3
                 E KO H/AU
L19          248 S E3-E17
                 E KO NAME/AU
L20           30 S E4
                 E SUZUKI TSUTOMU/AU
L21          792 S E3-E5
                 E TSUTOMU/AU
L22            2 S E3
L23            2 S E36
                 E TSUTOMU S/AU
                 SEL RN L1

     FILE 'REGISTRY' ENTERED AT 08:05:14 ON 15 JUN 2006
L24           11 S E1-E11
```

```
L25             STR
L26          50 S L25
L27        1550 S L25 FUL
                SAV L27 GEMBEH520/A
L28             STR L25
L29           1 S L28 SAM SUB=L27
L30          14 S L28 FUL SUB=L27
                SAV L30 GEMBEH520A/A
L31             STR L28
L32          49 S L31 SAM SUB=L27
L33         985 S L31 FUL SUB=L27
                SAV L33 GEMBEH520B/A
L34           9 S L24 NOT L30,L33
L35           2 S L24 NOT L34
L36             STR L28
L37             STR L36
L38           1 S L37 CSS SAM SUB=L30
L39          14 S L37 CSS FUL SUB=L30
                SAV L39 GEMBEH520C/A
L40             STR L37
L41           6 S L40 CSS SAM SUB=L33
L42         208 S L40 CSS FUL SUB=L33
                SAV L42 GEMBEH520D/A
L43         222 S L39,L42

     FILE 'HCAOLD' ENTERED AT 08:39:39 ON 15 JUN 2006
L44           1 S L43
                SEL AN
                EDIT E12 /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 08:40:19 ON 15 JUN 2006
L45           2 S E12
L46           1 S L45 NOT BEYER ?/AU
L47         416 S L43
L48          10 S L47 AND L1-L23
L49           9 S L47 AND TORAY?/PA,CS
L50          17 S L1,L48,L49
                E NAUSEA/CT
                E E3=ALL
                E NAUSEA/CT
                E E3+ALL
L51        1394 S E2
                E E4+ALL
L52        2960 S E2
L53        2889 S E3/BI OR E4/BI
L54        8785 S E7/BI
                E E5+ALL
L55        3139 S E6
L56        4436 S ANTIEMETI? OR ANTINAUSEA? OR ANTI()(EMETI? OR NAUSEA?)
                E NAUSEA
L57        9023 S E3-E14,E16-E21,E24,E31
                E VOMIT/CT
L58        2961 S E4-E6
                E E4+ALL
                E VOMIT
L59       10982 S E3-E19,E22-E27
L60           4 S L47 AND L51-L59
L61           1 S L47 AND (A61P001-08 OR A61P0001-08)/IPC,IC,ICM,ICS,ICA,ICI
L62           4 S L60,L61
L63           1 S L50 AND L62
```

```
L64           4 S L62,L63
L65          16 S L50 NOT L64

     FILE 'REGISTRY' ENTERED AT 08:49:02 ON 15 JUN 2006
L66           1 S MORPHINE/CN
L67          28 S C17H19NO3/MF AND 4766.1.6/RID
L68          27 S L67  AND MORPHIN?
L69          27 S L66,L68

     FILE 'HCAPLUS' ENTERED AT 08:50:16 ON 15 JUN 2006
L70        2789 S L69 (L) ADV/RL
L71          15 S L70 AND L47
L72          11 S L43 (L) (THU OR PAC OR PKT OR DMA OR BAC)/RL AND L71
L73          14 S L64,L72
L74           4 S L71 NOT L73
L75           2 S L74 NOT (2002:466697 OR 2000:68481)/AN
L76          16 S L73,L75
L77          11 S L76 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L78           5 S L76 NOT L77
L79         349 S L47 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L80         204 S L79 AND L43 (L) (THU OR PAC OR PKT OR DMA OR BAC)/RL
               E OPIODS/CT
L81        2461 S E68+OLD,NT (L) ADV/RL
L82          13 S L81 AND L80
L83          19 S L77,L82

     FILE 'REGISTRY' ENTERED AT 08:56:23 ON 15 JUN 2006

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:56:39 ON 15 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Jun 2006  VOL 144 ISS 25
FILE LAST UPDATED: 14 Jun 2006  (20060614/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> => d all hitstr

L84  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN   1961:48629  HCAPLUS
DN   55:48629
OREF 55:9374g-i,9375a
ED   Entered STN:  22 Apr 2001
```

TI Morphine derivatives. II. 3-Methoxy-4,5-epoxy-6,7-(2',3'-indolo)-N-methylmorphinan
AU Ekmekdzhyan, S. P.; Tatevosyan, G. T.
SO Izvest. Akad. Nauk Armyan. S.S.R., Khim. Nauki (1960), 13(No. 2-3), 201-5
DT Journal
LA Russian
CC 10G (Organic Chemistry: Heterocyclic Compounds)
GI For diagram(s), see printed CA Issue.
AB cf. CA 54, 22700a; Terzyan and Tatevosyan, CA 55, 7384i. Dihydrocodeinone (9 g.) and 5 g. PhHNNH2 was boiled 3 hrs. in 120 ml. alc. and 5 ml. concentrated H2SO4 and the precipitate was filtered off to give the H2SO4 salt of N-methylmorphinan (I), yield 95.1%, m. 322-3°. HCl used instead of H2SO4, gave 80.2% I.HCl, m. 294-5°. I.H2SO4 (13 g.) in 200 ml. 10% NaOH heated on the water bath 2.5-3 hrs. and the precipitate filtered off yielded 88.5% I, m. 125-6° (alc.); methiodide m. 287-8° (decomposition); picrate m. 209° (decomposition) (alc.). I.MeI (6.8 g.) boiled 6 hrs. in 50% NaOH and 50 ml. H2O, the precipitate filtered off, washed, dried, and extracted with Et2O, and the Et2O extract concentrated gave II, yield 68.8%, m. 163°; II.HCl m. 208° (decomposition). II.HCl (2.4 g.) and 6 ml. Ac2O was heated 18-20 hrs. in a sealed tube to 180°, 25 ml. H2O added and the mixture filtered. To the filtrate was added 60 ml. 10% NaOH and the whole distilled, with the distillate collected in 50 ml. 2N HCl. The HCl solution was concentrated and treated with AuCl3 to give the AuCl3 salt of β-dimethylaminoethanol, m. 201-2°.
IT **119079-09-3**, 6,7-(2',3'-Indolo)morphinan, 4,5-epoxy-3-methoxy-N-methyl- 124116-39-8, 6H-Benz[3,4]isobenzofuro[1,7-ab]carbazole, 12c-(2-dimethylaminoethyl)-5a,11,11b,12c-tetrahydro-1-methoxy- (and derivs.)
IT 57-27-2, Morphine (derivs.)
IT 124131-07-3, 4,5,5a,6,11,11b-Hexahydro-1-methoxy-15,15-dimethyl-5,12c-iminoethano-12cH-benz[3,4]isobenzofuro[1,7-ab]carbazolium iodide (preparation of)
IT **119079-09-3**, 6,7-(2',3'-Indolo)morphinan, 4,5-epoxy-3-methoxy-N-methyl- (and derivs.)
RN 119079-09-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole, 5,6,7,8,8a,9,14,14b-octahydro-1-methoxy-7-methyl-, (4bS,8R,8aR,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaold
FILE 'HCAOLD' ENTERED AT 08:57:17 ON 15 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all hitstr l44

L44 ANSWER 1 OF 1 HCAOLD COPYRIGHT 2006 ACS on STN
AN CA55:9374g CAOLD
TI morphine derivs. - (II) 3-methoxy-4,5-epoxy-6,7-(2',3'-indolo)-N-methylmorphinan
AU Ekmekdzhyan, S. P.; Tatevosyan, G. T.
IT **119079-09-3 119786-35-5** 124116-39-8 124116-40-1 124131-07-3
IT **119079-09-3 119786-35-5**
RN 119079-09-3 HCAOLD
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole, 5,6,7,8,8a,9,14,14b-octahydro-1-methoxy-7-methyl-, (4bS,8R,8aR,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119786-35-5 HCAOLD
CN 5,12c-Iminoethano-12cH-benz[3,4]isobenzofuro[1,7-ab]carbazole,

4,5,5a,6,11,11b-hexahydro-1-methoxy-15-methyl-, picrate (6CI) (CA INDEX NAME)

CM 1

CRN 119079-09-3
CMF C24 H24 N2 O2

Absolute stereochemistry.



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:57:30 ON 15 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Jun 2006 VOL 144 ISS 25
FILE LAST UPDATED: 14 Jun 2006 (20060614/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d l83 bib abs hitind hitstr retable tot

L83 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:531327 HCAPLUS
DN 141:76753
TI Oral drug delivery systems which form a network within the formulation and an outer surface for desirable drug release kinetics
IN Yum, Su Il; Schoenhard, Grant; Tipton, Arthur J.; Gibson, John W.; Middleton, John C.
PA Durect Corporation, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054542	A2	20040701	WO 2003-US40156	20031215 <--
	WO 2004054542	A3	20040826		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507522	AA	20040701	CA 2003-2507522	20031215 <--
	AU 2003299659	A1	20040709	AU 2003-299659	20031215 <--
	US 2004161382	A1	20040819	US 2003-737144	20031215 <--
	EP 1575569	A2	20050921	EP 2003-799943	20031215 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1774241	A	20060517	CN 2003-80109713	20031215 <--
PRAI	US 2002-433116P	P	20021213 <--		
	US 2003-517464P	P	20031104 <--		
	WO 2003-US40156	W	20031215 <--		

AB An oral dosage form comprises a formulation that, upon exposure to an aqueous environment, forms a network within the formulation and an outer surface, and wherein the formulation comprises a high viscosity liquid carrier material (e.g., sucrose acetate isobutyrate), a network former (e.g. cellulose acetate butyrate), and a drug. For example, a formulation comprising sucrose acetate isobutyrate, Et lactate, iso-Pr myristate, and cellulose acetate butyrate at the ratio of 65:27:3:5, was prepared and oxycodone (9 mg/g) was added. The mixture was heated to fill soft gel capsules.
IC ICM A61K0009-00
CC 63-6 (Pharmaceuticals)
IT Adrenoceptor antagonists
Anesthetics

Anti-infective agents
Anti-inflammatory agents
Antibiotics
Anticoagulants
Antiemetics
Antihistamines
Antimalarials
Antipsychotics
Antipyretics
Antiviral agents
Cardiovascular agents
Chemotherapy
Cholinergic antagonists
Decongestants
Dissolution
Fungicides
Human
Immunosuppressants
Nervous system depressants
Nervous system stimulants
Nutrients
Tranquilizers
Vaccines
(oral delivery systems forming network within formulation and outer surface for desirable drug release kinetics)

IT 51-64-9, Dextroamphetamine 57-27-2, Morphine, biological studies 57-42-1, Meperidine 58-00-4, Apomorphine 59-02-9, α-Tocopherol 62-67-9, Nalorphine 64-17-5, Ethyl alcohol, biological studies 64-39-1, Promedol 67-63-0, Isopropyl alcohol, biological studies 67-68-5, DMSO, biological studies 76-41-5, Oxymorphone 76-57-3, Codeine 76-58-4, Ethylmorphine 76-99-3, Methadone 77-07-6, Levorphanol 77-14-5, Propheptazine 77-15-6, Ethoheptazine 77-20-3, Alphaprodine 77-93-0, Triethyl citrate 84-66-2, Diethyl phthalate 100-51-6, Benzyl alcohol, biological studies 102-76-1, Triacetine 108-32-7, Propylene carbonate 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 113-45-1, Methylphenidate 120-51-4, Benzyl benzoate 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 126-13-6, Sucrose acetate isobutyrate 127-35-5, Phenazocine 131-11-3, Dimethyl phthalate 131-28-2, Narceine 143-52-2, Metopon 144-14-9, Anileridine 152-02-3, Levallorphan 302-41-0, Piritramide 357-56-2, Dextromoramide 359-83-1, Pentazocine 427-00-9, Desomorphine 428-37-5, Profadol 437-38-7, Fentanyl 441-61-2, Ethylmethylthiambutene 465-65-6, Naloxone 466-40-0, Isomethadone 466-97-7, Normorphine 466-99-9, Hydromorphone 467-18-5, Myrophine 467-83-4, Dipipanone 467-84-5, Phenadoxone 467-85-6, Normethadone 468-07-5, Phenomorphan 468-56-4, Hydroxypethidine 469-62-5, Propoxyphene 469-79-4, Ketobemidone 509-60-4, Dihydromorphine 509-67-1, Pholcodine 509-78-4, Dimenoxadol 524-84-5, Dimethylthiambutene 545-90-4, Dimepheptanol 552-25-0, Diampromide 561-27-3, Heroin 561-48-8, Norpipanone 561-76-2, Properidine 562-26-5, Phenoperidine 639-48-5, Nicomorphine 641-36-1, Apocodeine 872-50-4, NMP, biological studies 911-65-9, Etonitazene 1531-12-0, Norlevorphanol 3194-25-0, Nalorphine dinicotinate 3572-80-3, Cyclazocine 3734-52-9, Metazocine 3861-76-5, Clonitazene 4163-15-9, Cyclorphan 4406-22-8, Cyprenorphine 9004-36-8, Cellulose acetate butyrate 10061-32-2, Levophenacylmorphan 13495-09-5, Piminodine 14297-87-1, Benzylmorphine 14357-78-9, Diprenorphine 14521-96-1, Etorphine 15301-48-1, Bezitramide 15686-91-6, Propiram 16590-41-3, Naltrexone 16676-26-9, Nalmexone 20594-83-6, Nalbuphine 25322-68-3, PEG 400 25384-17-2, Allylprodine 27203-92-5, Tramadol 31692-85-0, Glycofurol 36292-66-7, Ethylketocyclazocine 42408-82-2,

Butorphanol 51931-66-9, Tilidine 52485-79-7, Buprenorphine 53648-55-8, Dezocine 54340-58-8, Meptazinol 55096-26-9, Nalmefene 56030-54-7, Sufentanil 56649-76-4, MR2266 58569-55-4, Metenkephalin 58822-25-6, Leuenkephalin 60617-12-1, β-Endorphin 61380-40-3, Lofentanil 67198-13-4 69671-17-6, α-Neoendorphin 71195-58-9, Alfentanil 72522-13-5, Eptazocine 72782-05-9, β-Funaltrexamine 73232-52-7, Methylnaltrexone 75644-90-5 75684-07-0, Bremazocine 78123-71-4, DAMGO 78995-14-9, Ohmefentanyl 82824-01-9, Naloxonazine 82970-70-5 85006-82-2, Dynorphin B 87151-85-7, Spiradoline 88161-22-2, Dynorphin A 88373-73-3 89352-67-0 93302-47-7, Naloxone methiodide 96744-75-1 103429-31-8, CTOP 105618-26-6, Norbinaltorphimine **111555-53-4**, Naltrindole 111555-58-9, Naltriben 118111-54-9, Cyprodime 119630-94-3, Naloxone benzoylhydrazone 126876-64-0 132875-61-7, Remifentanyl 149997-88-6, (D-Ala2,Glu4)deltorphin 153611-34-8, BNTX
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral delivery systems forming network within formulation and outer surface for desirable drug release kinetics)

IT **111555-53-4**, Naltrindole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral delivery systems forming network within formulation and outer surface for desirable drug release kinetics)

RN 111555-53-4 HCAPLUS

CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:60515 HCAPLUS

DN 140:105310

TI Therapeutic or preventive agent for **nausea/vomiting**

IN **Kawai, Koji; Saito, Akiyoshi; Suzuki, Tomohiko** ; Hasebe, Ko; **Suzuki, Tsutomu**

PA **Toray Industries, Inc., Japan**

SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2004007503 A1 20040122 WO 2003-JP8751 20030710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2492694 AA 20040122 CA 2003-2492694 20030710 <--
AU 2003281042 A1 20040202 AU 2003-281042 20030710 <--
EP 1522542 A1 20050413 EP 2003-741305 20030710 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1665820 A 20050907 CN 2003-816006 20030710 <--
US 2006052409 A1 20060309 US 2005-520809 20050202 <--
PRAI JP 2002-202657 A 20020711 <--
WO 2003-JP8751 W 20030710 <--
OS MARPAT 140:105310
GI



I



II

AB A therapeutic or preventive agent for **nausea/vomiting** which contains as an active ingredient either a morphinane derivative represented by the general formula (I): (wherein R1 represents cyclopropylmethyl, etc.; R2 and R3 each represents hydroxy, methoxy, etc.; R4 and R5 are bonded to each other to form -O-, etc.; R6 represents hydrogen, etc.; and Q represents (II) which has been optionally substituted, etc., provided that X represents NH, NMe, etc.) or a pharmacol. acceptable acid addition salt thereof. The compound or salt is useful in a medicine widely applicable to **vomiting** caused by drugs having emetic activity, especially in a therapeutic or preventive agent for **nausea/vomiting** induced by μ agonists represented by morphine.

IC ICM C07D0491-18
ICS C07D0491-22; C07D0491-08; A61K0045-00; A61K0031-485; **A61P0001-08**; A61P0025-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 27
ST morphinane deriv morphine mu opioid **antiemetic nausea vomiting**
IT **Antiemetics**
Nausea

Vomiting
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(μ-; morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

IT 75-75-2, Methane sulfonic acid 100-63-0, Phenylhydrazine 16590-41-3, Naltrexone
RL: RCT (Reactant); RACT (Reactant or reagent)
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

IT **111555-53-4P**, Naltrindole 122431-18-9P 129468-28-6P 189015-24-5P 200701-97-9P 214043-59-1P 647858-68-2P
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4P**, Naltrindole
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(morphinane derivs. as therapeutic or preventive agents for **nausea/vomiting** induced by μ agonists)

RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ananthan, S	1999	42	3527	Journal of Medicinal	HCAPLUS
Portoghese, P	1991	34	1715	Journal of Medicinal	HCAPLUS
Regents Of The Universi	1995			JP 09-505052 A	
Regents Of The Universi	1995			CA 2176013 A	HCAPLUS
Regents Of The Universi	1995			US 5464841 A	HCAPLUS
Regents Of The Universi	1995			US 5631263 A	HCAPLUS
Regents Of The Universi	1995			EP 727999 A1	HCAPLUS
Regents Of The Universi	1995			AU 9511731 A	HCAPLUS
Regents Of The Universi	1995			WO 9513071 A2	HCAPLUS
Regents Of The Universi	1995			WO 9513071 A3	HCAPLUS
The Wellcome Foundation	1993			JP 07-503247 A	
The Wellcome Foundation	1993			US 2002052007 A1	
The Wellcome Foundation	1993			US 5807858 A	HCAPLUS
The Wellcome Foundation	1993			US 5854249 A	HCAPLUS
The Wellcome Foundation	1993			US 5985880 A	HCAPLUS
The Wellcome Foundation	1993			US 6300332 B1	HCAPLUS
The Wellcome Foundation	1993			WO 9315062 A1	HCAPLUS
The Wellcome Foundation	1995			JP 09-501156 A	
The Wellcome Foundation	1995			CN 1054850 B	HCAPLUS
The Wellcome Foundation	1995			CN 1133593 A	HCAPLUS
The Wellcome Foundation	1995			ES 2149881 T3	HCAPLUS
The Wellcome Foundation	1995			CA 2168432 A	HCAPLUS
The Wellcome Foundation	1995			AU 692788 B	HCAPLUS
The Wellcome Foundation	1995			EP 711289 A1	HCAPLUS
The Wellcome Foundation	1995			EP 711289 B1	HCAPLUS
The Wellcome Foundation	1995			HU 72893 A2	HCAPLUS
The Wellcome Foundation	1995			AU 9472351 A	HCAPLUS
The Wellcome Foundation	1995			WO 9504051 A1	HCAPLUS
Toray Industries Inc	1991			JP 03-223288 A	HCAPLUS
Toray Industries Inc	1991			CA 2045481 A	HCAPLUS
Toray Industries Inc	1991			CA 2045481 B	HCAPLUS
Toray Industries Inc	1991			ES 2069100 T3	HCAPLUS
Toray Industries Inc	1991			JP 2906654 B2	HCAPLUS
Toray Industries Inc	1991			EP 456833 A1	HCAPLUS
Toray Industries Inc	1991			US 5332818 A	HCAPLUS
Toray Industries Inc	1991			NO 9102940 A	HCAPLUS
Toray Industries Inc	1991			WO 9107966 A1	HCAPLUS
Torray Industries Inc	1998			CN 1071117 B	HCAPLUS
Torray Industries Inc	1998			CN 1099617 A	HCAPLUS
Torray Industries Inc	1998			US 5714483 A	HCAPLUS

Torray Industries Inc	1998		EP 636371 A1	HCAPLUS
Torray Industries Inc	1998		AU 674379 B	HCAPLUS
Torray Industries Inc	1998		NO 9403070 A	HCAPLUS
Torray Industries Inc	1998		WO 9414445 A1	HCAPLUS
Torray Industries Inc	1998		AU 9457156 A	HCAPLUS
University Of Minnesota	1989		US 4816586 A	HCAPLUS
University Of Minnesota	1989		WO 8900995 A1	HCAPLUS

L83 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:745071 HCAPLUS
DN 140:281149
TI Dependence studies of new compounds in the rhesus monkey, rat and mouse (2002)
AU Aceto, M. D.; Bowman, E. R.; Harris, L. S.; Hughes, Larry D.; Kipps, B. R.; May, E. L.
CS Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
SO NIDA Research Monograph (**2003**), 183(Problems of Drug Dependence 2002), 191-227
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB Results of dependence-liability studies in rhesus monkeys, rat-infusion studies, and mouse-antinociception tests of new compds. using different assays are presented. All of the compds. submitted for evaluation were unknown except oxycodone and naltrindole.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(dependence studies of new compds. in rhesus monkey, rat and mouse)
IT **50-13-5**, Meperidine hydrochloride 52-28-8, Codeine phosphate 57-29-4, Nalorphine hydrochloride 64-31-3, Morphine sulfate 91-21-4 96-48-0, Butyrolactone 110-63-4, 1,4-Butanediol, biological studies 124-90-3, Oxycodone hydrochloride 127-35-5, Phenazocine 357-08-4, Naloxone hydrochloride 359-83-1, Pentazocine 575-19-9, 6,7-Benzomorphan 771-99-3, 4-Phenylpiperidine 3572-80-3, Cyclazocine 16676-29-2, Naltrexone hydrochloride 25265-75-2, Butanediol 63903-74-2 **111469-81-9**, Naltrindole hydrochloride 156053-89-3 497251-73-7 515836-00-7 515836-01-8 674346-95-3 674346-96-4 674346-98-6 674347-00-3 674347-02-5 674347-04-7 674347-05-8 674347-06-9 674347-08-1 674347-10-5 674347-12-7 674347-14-9 674347-16-1 674347-17-2 **674347-18-3** 674347-19-4 674347-20-7 674347-21-8 674347-23-0 674347-24-1 **674789-84-5** 674789-85-6 674789-86-7
RL: **ADV (Adverse effect, including toxicity)**; BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; BIOL (Biological study)
(dependence studies of new compds. in rhesus monkey, rat and mouse)
IT **50-13-5**, Meperidine hydrochloride **111469-81-9**, Naltrindole hydrochloride **674347-18-3 674789-84-5**
RL: **ADV (Adverse effect, including toxicity)**; BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; BIOL (Biological study)
(dependence studies of new compds. in rhesus monkey, rat and mouse)
RN 50-13-5 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 111469-81-9 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 674347-18-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-1-ol, 5,6,7,8,8a,9,14,14b-octahydro-8a-methoxy-7-propyl-, monohydrochloride, (4bS,8R,8aR,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 674789-84-5 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-1-ol, 5,6,7,8,8a,9,14,14b-octahydro-8a-methoxy-7-propyl-, (4bS,8R,8aS,14bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aceto, M	1969	36	225	Br J Pharmacol	HCAPLUS
Aceto, M	1978	50	203	Eur J Pharmacol	HCAPLUS
Aceto, M	1977	15	1	Pharmacol	MEDLINE
Atwell, L	1978	7	42	Lab Animal	
Deneau, G	1956			Doctoral Dissertatio	
Dewey, W	1970	175	435	J Pharmacol Exp Ther	HCAPLUS
Dewey, W	1971	179	652	J Pharmacol Exp Ther	HCAPLUS
D'Amour, F	1941	72	74	J Pharmacol Exp Ther	
Eddy, N	1953	107	385	J Pharmacol Exp Ther	HCAPLUS
Jacobson, A	1965	8	563	J Med Chem	HCAPLUS
Pearl, J	1966	154	319	J Pharmacol Exp Ther	HCAPLUS
Schild, M	1947	2	189	Br J Pharmacol	
Seevers, M	1936	56	147	J Pharmacol Exp Ther	HCAPLUS
Seevers, M	1963	I	565	Physiological Pharma	
Tallarida, R	1987		53	Manual of pharmacolo	
Teiger, D	1974	190	408	J Pharmacol Exp Ther	MEDLINE

L83 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:745070 HCAPLUS
DN 140:264237
TI Evaluation of new compounds for opioid activity (2002)
AU Woods, J. H.; Ko, M.-C.; Winger, G.; France, C. P.; Traynor, J. R.
CS Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, MI, USA
SO NIDA Research Monograph (**2003**), 183(Problems of Drug Dependence 2002), 170-190
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB Data on opioid abuse liability evaluations of compds. using rhesus monkeys are presented. These data usually involve in vitro evaluation in opioid binding assays, and the compds. may be evaluated for discriminative and reinforcing effects.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(activity; evaluation of new compds. for opioid activity)
IT 124-90-3 357-07-3 63903-74-2 156053-89-3 327027-61-2
478285-60-8 674346-94-2 674346-95-3 674346-96-4
674346-98-6 674347-00-3 674347-02-5 674347-04-7 674347-05-8
674347-06-9 674347-08-1 674347-10-5 674347-12-7 674347-14-9
674347-15-0 674347-16-1 674347-17-2 **674347-18-3**
674347-19-4 674347-20-7 674347-21-8 674347-22-9 674347-23-0
674347-24-1 674347-25-2 674347-26-3 674347-27-4 674347-29-6
674347-31-0 674347-34-3 674347-35-4
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; BIOL (Biological study)
(evaluation of new compds. for opioid activity)
IT **478285-60-8 674347-18-3**
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; BIOL (Biological study)
(evaluation of new compds. for opioid activity)
RN 478285-60-8 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-1-ol, 7-(cyclobutylmethyl)-8a-ethoxy-5,6,7,8,8a,9,14,14b-octahydro-14b-methyl-, monohydrochloride, (4bR,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 674347-18-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-1-ol,
5,6,7,8,8a,9,14,14b-octahydro-8a-methoxy-7-propyl-, monohydrochloride,
(4bS,8R,8aR,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bertalmio, A	1982	7	289	J Pharmacol Meth	HCAPLUS
Cheng, Y	1973	22	3099	Biochem Pharmacol	HCAPLUS
Clark, M	1997	283	501	J Pharmacol Exp Ther	HCAPLUS
Dykstra, L	1986	15	263	J Pharmacol Meth	HCAPLUS
Emmerson, P	1996	278	1121	J Pharmacol Exp Ther	HCAPLUS
France, C	1989	250	937	J Pharmacol Exp Ther	HCAPLUS
France, C	1990	252	600	J Pharmacol Exp Ther	HCAPLUS
France, C	1990	328	295	Progress in Clinical	HCAPLUS
Howell, L	1988	245	364	J Pharmacol Exp Ther	HCAPLUS
Lee, K	1999	378	323	Eur J Pharmacol	HCAPLUS
Traynor, J	1995	47	848	Mol Pharmacol	HCAPLUS
Winger, G	1989	24	135	Drug and Alc Depend	HCAPLUS
Zhu, J	1997	282	676	J Pharmacol Exp Ther	HCAPLUS

L83 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:62747 HCAPLUS
DN 139:17490
TI Sufentanil-related respiratory depression and antinociception in the dog: mediation by different receptor types
AU Latasch, Leo; Freye, Enno
CS Dept. of Anesthesiology and Pain Therapy, Krankenhaus Nordwest, Frankfurt/Main, Germany
SO Arzneimittel-Forschung (**2002**), 52(12), 870-876
CODEN: ARZNAD; ISSN: 0004-4172
PB Editio Cantor Verlag
DT Journal
LA English/German
AB The μ-receptor purportedly is considered the site responsible for the mediation of opioid-related respiratory depression. However, there is no equivocal understanding whether the same site is also responsible for antinociception. For blockade of effects, the selective μ-antagonist β-funaltrexamine (CAS 72782-05-9, β-FNA) was given intracerebroventricularly (i.c.v.) prior to increasing doses of sufentanil (CAS 60561-17-3) (3, 6 and 12 pg/kg) in the conscious dog. This was followed by the selective 6-antagonist naltrindole (CAS **111555-53-4**) (160 μg/kg). After one week, using the same dosages and the same animals, saline instead of β-FNA was given i.c.v., again followed by sufentanil and naltrindole. Arterial blood gases (paO2, paCO2) were used to demonstrate respiratory impairment while somatosensory-evoked potentials reflected sensory blockade. Maximal depression of paO2 was 73.9 with and 55.0 mmHg without β-FNA, while paCO2 rose to 44.7 without and to 35.0 mmHg with β-FNA ($p < 0.005$). In the evoked potential, maximal depression was 39.1% with and 92.7% without β-FNA ($p < 0.005$). Naltrindole reversed residual hypoxia, however, not hypercarbia or amplitude reduction of the evoked potential. For regulation of paO2, a μ-δ-receptor interaction is postulated while paCO2 and sensory blockade are affected solely by the opioid μ-site.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mediation by different receptor types of sufentanil-related respiratory depression and antinociception)
IT 72782-05-9, β-Funaltrexamine **111555-53-4**, Naltrindole
RL: **DMA (Drug mechanism of action)**; **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(mediation by different receptor types of sufentanil-related respiratory depression and antinociception)
IT **111555-53-4**, Naltrindole
RL: **DMA (Drug mechanism of action)**; **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(mediation by different receptor types of sufentanil-related respiratory depression and antinociception)
RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adams, J	1990	255	1027	J Pharmacol Exp Ther	HCAPLUS
Bailey, P	1993	79	49	Anesthesiology	MEDLINE
Blake, A	1996	3	967	Chem Biol	HCAPLUS
Chapmann, C	1979	3	791	Advances in Pain Res	
Chapmann, C	1982	14	327	Pain	
D'Amato, R	1984	81	2898	Proc Natl Acad Sci U	HCAPLUS
Freye, E	1992		147	International Narcot	
Freye, E	1988	4	138	J Clin Monit	
Freye, E	1987	75		Progress in Opioid R	
Freye, E	1994	21	S251	Regul Pept	
Gmerek, D	1985	235	296	J Pharmacol Exp Ther	HCAPLUS
Gmerek, D	1986	235	296	J Pharmacol Exp Ther	
Hoelle, V	1978	37	158	Fed Proc	
Holaday, J	1984		237	Central and Peripher	HCAPLUS
Holaday, J	1990	II	50	Opioids in Anesthesi	
Jaffe, J	1990	7	491	Goodman and Gilman's	
Jordon, C	1982	54	763	Br J Anaesth	
Knill, R	1978	49	244	Anesthesiology	HCAPLUS
Koht, A	1988	67	435	Anesth Analg	HCAPLUS
Leysen, J	1983	87	209	Eur J Pharmacol	HCAPLUS
Ling, G	1985	232	149	J Pharmacol Exp Ther	HCAPLUS
Liu-Chen, L	1987	32	321	Mol Pharmacol	HCAPLUS
Martin, W	1976	197	517	J Pharmacol Exp Ther	HCAPLUS
Martin, W	1981	28	1547	Mini-Symposium II Mu	HCAPLUS
Morin-Surun, M	1984	98	241	Eur J Pharmacol	HCAPLUS
Nunn, J	1987			Applied Respiratory	
Pan, Y	1999	56	396	Mol Pharm	HCAPLUS
Patrick, P	1991	46	85	Anaesthesia	
Pazos, A	1983	87	1309	Eur J Pharmacol	
Portoghese, P	1988	146	185	Eur J Pharmacol	HCAPLUS
Portoghese, P	1988	31	281	J Med Chem	HCAPLUS
Raynor, K	1994	45	330	Mol Pharmacol	HCAPLUS
Recht, L	1987	140	209	Eur J Pharmacol	HCAPLUS
Rohdewald, P	1982	12	329	Pain	HCAPLUS
Rothman, R	1981	72	365	Eur J Pharmacol	HCAPLUS
Rothman, R	1988	247	405	J Pharmacol Exp Ther	HCAPLUS
Sanchez-Blazquez, P	1989	159	9	Eur J Pharmacol	HCAPLUS
Sebel, P	1988	69		Anesthesiology	
Sebel, P	1985	57	841	Br J Anaesth	MEDLINE
Strandling, J	1985	21	317	Bull Eur Physiother	

Takemori, A	1992	32	239	Annu Rev Pharmacol T	HCAPLUS
Valentino, R	1983	32	2887	Life Sci	HCAPLUS
van Leersum, E	1911	142	377	Pflugers Arch ges Ph	
Vaught, J	1982	30	1443	Life Sci	HCAPLUS
Ward, S	1982	80	377	Eur J Pharmacol	HCAPLUS
Ward, S	1983	87	1	Eur J Pharmacol	HCAPLUS
Ward, S	1982	8	388	Proc Soc Neurosci	
Wauquier, A	1982		78	Alfentanil	
Yaksh, T	1983	226	303	J Pharmacol Exp Ther	HCAPLUS

L83 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:762005 HCAPLUS
DN 138:331550
TI Dependence studies of new compounds in the rhesus monkey, rat and mouse (2001)
AU Aceto, M. D.; Bowman, E. R.; Harris, L. S.; Kipps, B. R.; May, E. L.
CS Department of Pharmacology and Toxicology, School of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA, USA
SO NIDA Research Monograph (**2002**), 182(Problems of Drug Dependence 2001), 157-209
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB Thirty-three compds. were submitted for testing by the Biol. Coordinator of the University of Maryland School of Pharmacy. All compds. except (γ)-hydroxybutyric acid, caffeine, lobeline, and agmatine were unknown to the testers when submitted. Compds. were tested in various ways for activity and dependence liability, including substitution-for-morphine test, precipitated-withdrawal test, and primary-phys.-dependence study in monkeys and rats, and antinociception tests in mice. These studies were conducted under the auspices of the Drug Evaluation Committee in association with the College on Problems of Drug Dependence.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug dependence studies of new compds. in the rhesus monkey, rat and mouse)
IT 90-69-7, Lobeline 502-85-2, γ-Hydroxybutyric acid sodium salt 1421-32-5 2482-00-0, Agmatine sulfate 50915-69-0 113590-09-3 131733-92-1, NCS-382 142036-44-0 142036-52-0 177185-73-8 220662-95-3 321594-10-9 **342884-62-2** 514826-67-6 **515835-91-3** 515835-93-5 515835-94-6 515835-95-7 515835-96-8 515835-97-9 515835-98-0 515835-99-1 515836-00-7 515836-01-8 515836-02-9 515836-04-1 515836-06-3 515836-07-4 515836-08-5 515836-10-9 515836-11-0 515836-12-1 518027-28-6, (+)-Oripavine 518052-04-5, NIH 11026
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(drug dependence studies of new compds. in the rhesus monkey, rat and mouse)
IT **342884-62-2 515835-91-3**
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(drug dependence studies of new compds. in the rhesus monkey, rat and mouse)

RN 342884-62-2 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 5,6,7,8,14,14b-hexahydro-7-(2-methyl-2-propenyl)-, (4bS,8R,8aS,14bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 515835-91-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(2-cyclohexylethyl)-5,6,7,8,14,14b-hexahydro-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aceto, M	1969	36	225	Br J Pharmacol	HCAPLUS
Aceto, M	1978	50	203	Eur J Pharmacol	HCAPLUS
Aceto, M	1977	15	1	Pharmacol	MEDLINE

Atwell, L	1978	7	42	Lab Animal	
Deneau, G	1956			Doctoral Dissertatio	
Dewey, W	1970	175	435	J Pharmacol Exp Ther	HCAPLUS
Dewey, W	1971	179	652	J Pharmacol Exp Ther	HCAPLUS
D'Amour, F	1941	72	74	J Pharmacol Exp Ther	
Eddy, N	1953	107	385	J Pharmacol Exp Ther	HCAPLUS
Jacobson, A	1965	8	563	J Med Chem	HCAPLUS
Pearl, J	1966	154	319	J Pharmacol Exp Ther	HCAPLUS
Schild, M	1947	2	189	Br J Pharmacol	
Seevers, M	1936	56	147	J Pharmacol Exp Ther	HCAPLUS
Seevers, M	1963	I	565	Physiological Pharma	
Tallarida, R	1987		53	Manual of pharmacolo	
Teiger, D	1974	190	408	J Pharmacol Exp Ther	MEDLINE

L83 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:762004 HCAPLUS
DN 138:331549
TI Evaluation of new compounds for opioid activity (2001)
AU Woods, J. H.; Traynor, J. R.
CS The Drug Abuse Basic Research Program, Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, MI, USA
SO NIDA Research Monograph (**2002**), 182(Problems of Drug Dependence 2001), 139-153
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB This report contains information on opioid abuse liability evaluations on compds. that have been submitted to the Drug Evaluation Committee of the College and released for publication by the submitters. The information obtained usually involves in vitro evaluation in opioid binding assays. In addition, the compds. may be evaluated for discriminative and reinforcing effects. Analgesic and respiratory function assays are also possible. These behavioral assessments are conducted in rhesus monkeys (see Appendix). Usually when limited information is provided (e.g., in vitro assessment only), it is because the sample provided by the submitter was insufficient to carry out further evaluation.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity and receptor binding)
IT 1421-32-5, NIH 11018 16676-29-2, Naltrexone hydrochloride 50915-69-0, NIH 11017 53152-21-9, Buprenorphine hydrochloride 109582-45-8 **111469-81-9**, Naltrindole hydrochloride 117332-69-1, Clocinnamox 131733-92-1, NCS-382 142036-44-0, NIH 11014 142036-52-0, NIH 11013 153611-34-8, BNTX 160625-41-2, NIH 10095 177185-73-8, NIH 10945 321594-10-9, NIH 10992 **342884-62-2**, NIH 10978 **515835-91-3**, NIH 10979 515835-93-5, NIH 10994 515835-95-7, NIH 11003 515835-96-8, NIH 11004 515835-97-9, NIH 11005 515835-98-0, NIH 11006 515835-99-1, NIH 11007 515836-00-7, NIH 11011 515836-01-8, NIH 11012 515836-02-9, Thevinone oxalate 515836-04-1, NIH 11020 515836-06-3, NIH 11021 515836-07-4, NIH 11022 515836-08-5, NIH 11023 515836-10-9, NIH 11025 515836-11-0, NIH 11028 515836-12-1, NIH 11037 518052-04-5, NIH 11026
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity and receptor binding)

IT **111469-81-9**, Naltrindole hydrochloride **342884-62-2**, NIH 10978 **515835-91-3**, NIH 10979
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity and receptor binding)
RN 111469-81-9 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 342884-62-2 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 5,6,7,8,14,14b-hexahydro-7-(2-methyl-2-propenyl)-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 515835-91-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(2-cyclohexylethyl)-5,6,7,8,14,14b-hexahydro-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bertalmio, A	1982	7	289	J Pharmacol Meth	HCAPLUS
Cheng, Y	1973	22	3099	Biochem Pharmacol	HCAPLUS
Clark, M	1997	283	501	J Pharmacol Exp Ther	HCAPLUS
Dykstra, L	1986	15	263	J Pharmacol Meth	HCAPLUS
Emmerson, P	1996	278	1121	J Pharmacol Exp Ther	HCAPLUS
France, C	1989	250	937	J Pharmacol Exp Ther	HCAPLUS
France, C	1990	252	600	J Pharmacol Exp Ther	HCAPLUS
France, C	1990	328	295	Progress in Clinical	HCAPLUS
Howell, L	1988	245	364	J Pharmacol Exp Ther	HCAPLUS
Lee, K	1999	378	323	Eur J Pharmacol	HCAPLUS
Traynor, J	1995	47	848	Mol Pharmacol	HCAPLUS
Winger, G	1989	24	135	Drug and Alc Depend	HCAPLUS
Zhu, J	1997	282	676	J Pharmacol Exp Ther	HCAPLUS

L83 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:581650 HCAPLUS
DN 138:231585
TI Effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine
AU Rauhut, Anthony S.; Gehrke, Brenda J.; Phillips, Scott B.; Bardo, Michael T.
CS Department of Psychology, University of Kentucky, Lexington, KY, 40506-0044, USA
SO Pharmacology, Biochemistry and Behavior (**2002**), 73(3), 611-622
CODEN: PBBHAU; ISSN: 0091-3057
PB Elsevier Science Inc.
DT Journal
LA English
AB In a series of expts., the ability of selective μ- (β-funaltrexamine, β-FNA), δ- (naltrindole, nalt) and κ-

(nor-binaltorphimine, nor-BNI) opioid receptor antagonists to attenuate the unconditioned and conditioned hyperactive effects of morphine was examined For comparison, the nonselective opioid receptor antagonist naloxone (nalx) was also examined Locomotor activity served as the behavioral measure. Experiment 1 found that doses of 1 and 4, but not 16 mg/kg, of morphine effectively produced conditioned hyperactivity (CH). Expts. 2a-d found that β-FNA, nalt, nor-BNI and nalx, resp., attenuated unconditioned morphine-induced hyperactivity. Expts. 3a-c, however, found that none of the selective antagonists, given individually, attenuated CH. In contrast, nalx did attenuate CH (Experiment 3d). Collectively results suggest that the unconditioned and conditioned hyperactive responses to morphine are mediated by different receptor systems and that activation of multiple opioid-receptor subtypes mediate expression of CH.

CC 1-11 (Pharmacology)

IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine)

IT 72782-05-9, β-Funaltrexamine 105618-26-6, Nor-binaltorphimine
111555-53-4, Naltrindole
RL: **PAC (Pharmacological activity)**; BIOL (Biological study)
(effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine)

IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine)

RN 57-27-2 HCAPLUS

CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole
RL: **PAC (Pharmacological activity)**; BIOL (Biological study)
(effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine)

RN 111555-53-4 HCAPLUS

CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol,
7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ayhan, I	1973	29	317	Psychopharmacology	HCAPLUS
Babbini, M	1976	46	213	Br J Pharmacol	
Bals-Kubik, R	1993	264	489	J Pharmacol Exp Ther	HCAPLUS
Bardo, M	1995	19	39	Neurosci Biobehav Re	HCAPLUS
Beatty, W	1983	19	397	Pharmacol, Biochem B	HCAPLUS
Beninger, R	1986	38	1425	Life Sci	HCAPLUS
Bertalmio, A	1989	251	455	J Pharmacol Exp Ther	HCAPLUS
Braida, D	1994	271	497	Eur J Pharmacol	HCAPLUS
Broadbear, J	1994	115	311	Psychopharmacology	HCAPLUS
Endoh, T	1992	316	30	Arch Int Pharmacodyn	HCAPLUS
Ettenberg, A	1982	78	204	Psychopharmacology	HCAPLUS
Gold, L	1989	1	209	Behav Pharmacol	
Hand, T	1989	98	61	Psychopharmacology	HCAPLUS
Horan, P	1992	260	1237	J Pharmacol Exp Ther	HCAPLUS
Itzhak, Y	2000	152	216	Psychopharmacology	HCAPLUS
Iwamoto, E	1986	6	327	Alcohol Drug Res	MEDLINE
Iwamoto, E	1981	217	451	J Pharmacol Exp Ther	HCAPLUS
Jackson, H	1989	28	1427	Neuropharmacology	HCAPLUS
Kitchen, I	1990	100	685	Br J Pharmacol	HCAPLUS
Kitchen, I	1990		2321	New leads in opioid	
Koob, G	1984	229	481	J Pharmacol Exp Ther	HCAPLUS
McNamara, R	1992	108	147	Psychopharmacology	HCAPLUS
Mucha, R	1982	243	91	Brain Res	HCAPLUS
Mucha, R	1981	95	351	J Comp Physiol Psych	HCAPLUS
Mucha, R	1985	86	274	Psychopharmacology	HCAPLUS
Negus, S	1993	265	1245	J Pharmacol Exp Ther	HCAPLUS
Neisewander, J	1987	93	314	Psychopharmacology	HCAPLUS
Neisewander, J	1990	100	201	Psychopharmacology	HCAPLUS
Oka, T	1976	47	243	Psychopharmacology	HCAPLUS
Piepponen, T	1997	58	275	Pharmacol, Biochem B	HCAPLUS
Rescorla, R	1967	74	71	Psychol Bull	MEDLINE
Schulze, G	1991	38	77	Pharmacol, Biochem B	HCAPLUS
Shippenberg, T	1987	436	234	Brain Res	HCAPLUS
Shippenberg, T	2000	151	351	Psychopharmacology	HCAPLUS
Swerdlow, N	1985	23	499	Pharmacol, Biochem B	HCAPLUS
Swerdlow, N	1984	84	163	Psychopharmacology	HCAPLUS
Vezina, P	1984	20	925	Pharmacol, Biochem B	HCAPLUS
Wei, E	1973	28	35	Psychopharmacologia	HCAPLUS

L83 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:575294 HCAPLUS
DN 137:135051
TI Compositions and methods for optimizing UDP glucuronosyltransferase UGT2B7 drug substrate dosings and for predicting UGT2B7 drug substrate toxicity
IN Ratain, Mark J.; Innocenti, Federico; Das, Soma; Iyer, Lalitha; Sawyer, Michael
PA University of Chicago, USA
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059375	A2	20020801	WO 2002-US2083	20020125 <--
	WO 2002059375	C2	20021031		
	WO 2002059375	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002240066	A1	20020806	AU 2002-240066	20020125 <--
	US 2003099960	A1	20030529	US 2002-57834	20020125 <--
PRAI	US 2001-264534P	P	20010126 <--		
	WO 2002-US2083	W	20020125 <--		

AB The invention concerns UGT2B7 and its ability to glucuronidate various drugs, including epirubicin. It discloses methods and compns. for determining the level of UGT2B7 activity based on genetic composition, and consequently, allows dosing of UGT2B7-glucuronidated drugs to be improved or optimized based on a patient's level of predicted UGT2B7 activity. It further discloses methods of treatment in which UGT2B7 substrates are administered to patients as part of a treatment regimen.
IC ICM C12Q0001-68
CC 1-2 (Pharmacology)
Section cross-reference(s): 7
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(UDP glucuronosyltransferase UGT2B7 drug substrate dosing optimization and UGT2B7 drug substrate toxicity prediction)
IT **57-27-2**, Morphine, biological studies 56420-45-2, Epirubicin
RL: **ADV (Adverse effect, including toxicity)**; PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(UDP glucuronosyltransferase UGT2B7 drug substrate dosing optimization and UGT2B7 drug substrate toxicity prediction)
IT 50-27-1, Estriol 53-41-8, Androsterone 53-86-1, Indomethacin 56-75-7, Chloramphenicol 62-67-9, Nalorphine 64-19-7D, Acetic acid, derivs. 69-72-7D, Salicylic acid, derivs. 76-41-5, Oxymorphone 76-57-3, Codeine 77-07-6, Levorphanol 79-09-4D, Propionic acid, derivs. 79-31-2D, Isobutyric acid, derivs. 99-66-1, Valproic acid 103-82-2D, Phenylacetic acid, derivs. 302-79-4, all-trans-Retinoic acid 465-65-6, Naloxone 466-97-7, Normorphine 466-99-9, Hydromorphone

467-04-9D, Oripavine, derivs. **467-15-2**, Norcodeine 468-10-0D, Morphinan, derivs. 481-30-1, Epitestosterone 525-66-6, Propranolol 604-75-1, Oxazepam 846-50-4, Temazepam 882-09-7, Clofibric acid 3131-23-5, 4-Hydroxyestrone 14357-78-9, Diprenorphine 15687-27-1, Ibuprofen 16590-41-3, Naltrexone **20594-83-6**, Nalbuphine 21256-18-8, Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 29679-58-1, Fenoprofen 30516-87-1, Zidovudine 33005-95-7, Tiaprofenic acid 33369-31-2, Zomepirac 41340-25-4, Etodolac 51234-28-7, Benoxaprofen 52485-79-7, Buprenorphine 55096-26-9, Nalmefene 56420-45-2D, Epirubicin, analogs 60021-32-1, 4-Hydroxyestriol 78715-23-8, Norbuprenorphine **111555-53-4**, Naltrindole 111555-58-9, Naltriben
RL: **ADV (Adverse effect, including toxicity)**; **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(UDP glucuronosyltransferase UGT2B7 drug substrate dosing optimization and UGT2B7 drug substrate toxicity prediction)

IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(UDP glucuronosyltransferase UGT2B7 drug substrate dosing optimization and UGT2B7 drug substrate toxicity prediction)

RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **467-15-2**, Norcodeine **20594-83-6**, Nalbuphine **111555-53-4**, Naltrindole
RL: **ADV (Adverse effect, including toxicity)**; **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(UDP glucuronosyltransferase UGT2B7 drug substrate dosing optimization and UGT2B7 drug substrate toxicity prediction)

RN 467-15-2 HCAPLUS
CN Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 20594-83-6 HCAPLUS
CN Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:875025 HCAPLUS
DN 134:172951
TI The role of opioid receptors in morphine withdrawal in the infant rat

AU McPhie, A. A.; Barr, G. A.
CS Biopsychology Doctoral Program, Department of Psychology, Hunter College, City University of New York, New York, NY, 10021, USA
SO Developmental Brain Research (**2000**), 124(1,2), 73-80
CODEN: DBRRDB; ISSN: 0165-3806
PB Elsevier Science B.V.
DT Journal
LA English
AB Exposure to opiates such as morphine can lead to psychol. and phys. dependence in both adult and infant humans. Infant rats experience opiate withdrawal behaviors that are qual. different from the withdrawal behaviors displayed by adult rats. In the adult, withdrawal is largely mediated by the μ-opioid receptor. We sought to understand more about what role each opioid receptor (μ, κ, and δ) plays in the display of the phys. withdrawal in the infant rat. Beginning on postnatal day 1, infant rats were injected with morphine sulfate twice a day for 6.5 days. On the afternoon of the seventh day the infant rats were given an i.c. injection of a vehicle, the μ-opioid receptor antagonist CTOP, the κ-opioid receptor antagonist nor-BNI, or the δ-opioid receptor antagonist naltrindole. CTOP precipitated withdrawal behaviors in the 7-day-old rat in a dose-dependent manner. Neither nor-BNI nor naltrindole induced any significant changes in the frequency of the withdrawal behaviors. These data suggest that in the infant rat control of certain behavioral withdrawal signs is modulated primarily by the μ-opioid receptor, as is the case in the adult rat.
CC 1-11 (Pharmacology)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(role of opioid receptors in morphine withdrawal in infant rat)
IT 103429-31-8, CTOP 105618-26-6, Nor-BNI **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(role of opioid receptors in morphine withdrawal in infant rat)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(role of opioid receptors in morphine withdrawal in infant rat)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(role of opioid receptors in morphine withdrawal in infant rat)

RN 111555-53-4 HCAPLUS

CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Barr, G	1986	29	145	Dev Brain Res	HCAPLUS
Carden, S	1991	62	17	Dev Brain Res	HCAPLUS
Cowan, A	1988	246	950	J Pharmacol Exp Ther	HCAPLUS
De Vries, T	1990	54	63	Dev Brain Res	HCAPLUS
Dinges, D	1980	209	619	Science	HCAPLUS
Fanselow, M	1988	31	431	Pharmacol Biochem Be	HCAPLUS
Finnegan, L	1985	44	2314	Fed Proc	MEDLINE
Geller, L	1966	18	221	Psychol Rep	MEDLINE
Georges, F	1998	109	187	Dev Brain Res	HCAPLUS
Inturrisi, C	1997	9	110	Semin Neurosci	HCAPLUS
Jones, K	1995	109	1189	Behav Neurosci	MEDLINE
Kornblum, H	1987	37	21	Dev Brain Res	HCAPLUS
Maldonado, R	1990	520	247	Brain Res	HCAPLUS
Maldonado, R	1992	31	1231	Neuropharmacology	HCAPLUS
Matthes, H	1996	383	819	Nature	HCAPLUS
McDowell, J	1987	12	397	Brain Res Rev	HCAPLUS
Nestler, E	1992	12	2439	J Neurosci	HCAPLUS
Oommen, A	1995	1	619	Analgesia	HCAPLUS
Rajegowda, B	1972	81	532	J Pediatr	MEDLINE
Rius, R	1991	58	237	Dev Brain Res	HCAPLUS
Simonin, F	1998	17	886	EMBO J	HCAPLUS
Spanagel, R	1994	115	121	Psychopharmacology	HCAPLUS
Stevens, C	1989	166	467	Eur J Pharmacol	HCAPLUS
Suzuki, T	1992	213	91	Eur J Pharmacol	HCAPLUS
Suzuki, T	1990	13	s133	J Pharmacobio-Dyn	
Szucs, M	1990	54	1419	J Neurochem	HCAPLUS
Thornton, S	1997	340	161	Eur J Pharmacol	HCAPLUS
Truijillo, K	1991	3	915	New Biologist	
Windh, R	1995	273	1361	J Pharmacol Exp Ther	HCAPLUS
Young, G	1985	23	457	Pharmacol Biochem Be	HCAPLUS

Zhu, Y |1998 |18 |2538 |J Neurosci |HCAPLUS

L83 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:360622 HCAPLUS
DN 131:179130
TI Dependence studies of new compounds in the rhesus monkey, rat and mouse (1996)
AU Aceto, M. D.; Bowman, E. R.; Harris, L. S.; May, E. L.
CS Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
SO NIDA Research Monograph (**1997**), Volume Date 1996, 174(Problems of Drug Dependence 1996), 338-395
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal; General Review
LA English
AB A review, with 17 refs. Evaluation of opioid agonists and antagonists in dependence-liability studies in rhesus monkeys, rat-infusion studies, and mouse-antinociception tests is presented with some new results.
CC 1-0 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dependence studies of opioids in rhesus monkey, rat and mouse)
IT 64-31-3, NIH 0001 76-41-5, NIH 10323 143-98-6, NIH 4591 357-08-4, NIH 7890 16030-39-0, NIH 10873 16676-29-2, NIH 8503 31036-80-3, NIH 10868 67198-13-4, NIH 10533 78123-71-4, NIH 10891 82824-01-9, NIH 10894 89352-67-0, NIH 10893 94021-22-4, NIH 10854 100111-01-1, NIH 10892 105618-27-7, NIH 10588 111469-84-2, NIH 10590
111469-88-6, NIH 10842 **111555-53-4**, NIH 10589
124439-07-2, NIH 10672 156727-74-1, NIH 10815 240422-35-9, NIH 10797
240422-36-0, NIH 10798 240422-37-1, NIH 10806 240422-38-2, NIH 10807
240422-39-3, NIH 10808 240422-40-6, NIH 10834 240422-41-7, NIH 10835
240422-42-8, NIH 10836 240422-43-9, NIH 10844 240422-45-1, NIH 10845
240422-46-2, NIH 10847 240422-47-3, NIH 10848 240422-48-4, NIH 10849
240422-49-5, NIH 10852 240422-50-8, NIH 10853 240422-51-9, NIH 10855
240422-52-0, NIH 10856 240422-53-1, NIH 10857 240422-54-2, NIH 10858
240422-55-3, NIH 10862 240422-56-4, NIH 10863 240422-58-6, NIH 10864
240422-60-0, NIH 10865 240422-62-2, NIH 10866 240422-63-3, NIH 10869
240422-64-4, NIH 10872
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(dependence studies of opioids in rhesus monkey, rat and mouse)
IT **111469-88-6**, NIH 10842 **111555-53-4**, NIH 10589
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(dependence studies of opioids in rhesus monkey, rat and mouse)
RN 111469-88-6 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 5,6,7,8,14,14b-hexahydro-7-methyl-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aceto, M	1969	36	225	Br J Pharmacol	HCAPLUS
Aceto, M	1978	50	203	Eur J Pharmacol	HCAPLUS
Aceto, M	1977	15	1	Pharmacol	MEDLINE
Atwell, L	1978	7	42	Lab Animal	
Crain, S	1995	92	1	Proc Natl Acad Sci	
Deneau, G	1956			Doctoral Dissertatio	
Dewey, W	1970	175	435	J Pharmacol Exp Ther	HCAPLUS
Dewey, W	1971	179	652	J Pharmacol Exp Ther	HCAPLUS
D'Amour, F	1941	72	74	J Pharmacol Exp Ther	
Eddy, N	1953	107	385	J Pharmacol Exp Ther	HCAPLUS
Jacobson, A	1965	8	563	J Med Chem	HCAPLUS
Pearl, J	1966	154	319	J Pharmacol Exp Ther	HCAPLUS
Schild, M	1947	2	189	Br J Pharmacol	
Seevers, M	1936	56	147	J Pharmacol Exp Ther	HCAPLUS
Seevers, M	1963	I	565	Physiological Pharma	
Tallarida, R	1987		53	Manual of pharmacolo	

Teiger, D |1974 |190 |408 |J Pharmacol Exp Ther|MEDLINE

L83 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:359362 HCAPLUS
DN 131:179678
TI Evaluation of new compounds for opioid activity (1998)
AU Woods, J. H.; Winger, G.; Traynor, J. R.; Medzihradsky, F.; Smith, C. B.
CS Departments of Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, MI, USA
SO NIDA Research Monograph (**1999**), Volume Date 1998, 179(Problems of Drug Dependence, 1998), 365-380
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB New compds. were tested for their opioid abuse liability by the Drug Evaluation Committee of the College.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(evaluation of new compds. for opioid activity)
IT 122517-78-6 129468-30-0 162549-77-1 188607-09-2 188607-29-6
188607-39-8 197242-25-4 205375-36-6 219927-14-7 **219927-15-8**
240415-25-2 240415-26-3 240415-29-6 240415-30-9 240415-32-1
240415-34-3 240418-82-0 240418-83-1 240418-84-2
240418-85-3 240418-90-0 240418-94-4 240418-97-7
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(evaluation of new compds. for opioid activity)
IT **219927-15-8 240415-34-3**
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(evaluation of new compds. for opioid activity)
RN 219927-15-8 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 5,6,7,8,14,14b-hexahydro-7-(phenylmethyl)-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 240415-34-3 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclohexylmethyl)-5,6,7,8,14,14b-hexahydro-, monohydrochloride, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bertalmio, A	1982	7	289	J Pharmacol Meth	HCAPLUS
Cheng, Y	1973	22	3099	Biochem Pharmacol	HCAPLUS
Clark, M	1988	148	343	Eur J Pharmacol	HCAPLUS
Clark, M	1987	26	1763	Neuropharmacol	HCAPLUS
Dykstra, L	1986	15	263	J Pharmacol Meth	HCAPLUS
Emmerson, P	1994	271	1630	J Pharmacol Exp Ther	HCAPLUS
France, C	1989	250	937	J Pharmacol Exp Ther	HCAPLUS
France, C	1990	252	600	J Pharmacol Exp Ther	HCAPLUS

France, C	1990	328	295	Progress in Clinical	HCAPLUS
Howell, L	1988	245	364	J Pharmacol Exp Ther	HCAPLUS
Medzihradsky, F	1992	27	67	J Pharmacol Meth	MEDLINE
Medzihradsky, F	1987	76	349	NIDA Res Monogr	HCAPLUS
Perrine, T	1972	61	86	J Pharm Sci	HCAPLUS
Smith, C	1986	76	288	NIDA Res Monogr	
Smith, C	1989		65	The International Na	HCAPLUS
Solomon, R	1982	21	1329	Neuropharmacol	HCAPLUS
Winger, G	1989	24	135	Drug and Alc Depend	HCAPLUS
Woods, J	1979		429	Mechanisms of Pain a	HCAPLUS

L83 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:557203 HCAPLUS
DN 130:90325
TI Opioid inhibition of rat medial vestibular nucleus neurons in vitro and its dependence on age
AU Roslan Sulaiman, M.; Dutia, M. B.
CS Department of Physiology, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK
SO Experimental Brain Research (**1998**), 122(2), 196-202
CODEN: EXBRAP; ISSN: 0014-4819
PB Springer-Verlag
DT Journal
LA English
AB Extracellular and whole-cell patch clamp intracellular recordings were made from rat medial vestibular nucleus (MVN) neurons in vitro, and their responses to selective μ-, κ- and δ-opioid receptor agonists and antagonists were examined Of 127 neurons tested, the large majority were inhibited in a dose-dependent manner by the δ-opioid receptor agonists [d-Ala2, d-Leu5]-enkephalin (DADLE) and [d-Pen2, Pen5]-enkephalin (DPLPE). The μ-opioid receptor agonist morphine and the κ-receptor agonist U50,488 did not affect the tonic discharge rate of any of the 63 MVN cells tested. The δ-receptor antagonist naltrindole effectively antagonized the inhibitory effects of DADLE and DPLPE. Weak excitatory responses to high doses of DADLE were seen in only two MVN cells. These results demonstrate the presence of δ- but not μ- or κ-opioid receptors on tonically active MVN neurons. Whole-cell intracellular recordings from MVN cells in a current clamp showed that the DADLE-induced inhibition was accompanied by membrane hyperpolarization and decrease in input resistance, while voltage clamp expts. showed that DADLE induced an outward membrane current that was reduced but not abolished by 20 mM tetraethylammonium bromide. Thus the mechanisms of action of DADLE in inhibiting MVN cells involve the potentiation of outward K currents, in a similar way to the effects of opioids in other areas of brain. The inhibitory effects of DADLE increased linearly with age, so that the responses to DADLE in the youngest animals used here (60-80 g, approx. 3 wk of age) were relatively small, increasing significantly over the following 2-3 wk. This age-dependence may be due to post-natal changes in the d. of δ-opiate receptors or the efficacy of the signalling pathways activated by them in the MVN cells over this time.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(opioid inhibition of rat medial vestibular nucleus neurons in vitro and its dependence on age)
IT **57-27-2**, Morphine, biological studies 71-91-0, Tetraethylammonium bromide **63631-40-3**, DADLE 67198-13-4,

U50488 88373-72-2 **111555-53-4**, Naltrindole
RL: **ADV (Adverse effect, including toxicity)**; **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(opioid inhibition of rat medial vestibular nucleus neurons in vitro and its dependence on age)

IT **57-27-2**, Morphine, biological studies **63631-40-3**, DADLE **111555-53-4**, Naltrindole
RL: **ADV (Adverse effect, including toxicity)**; **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(opioid inhibition of rat medial vestibular nucleus neurons in vitro and its dependence on age)

RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 63631-40-3 HCAPLUS
CN D-Leucine, L-tyrosyl-D-alanylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Beitz, A	1987	20	409	Neuroscience	HCAPLUS
Blanton, M	1989	30	203	J Neurosci Methods	MEDLINE
Cameron, S	1997	8	2595	Neuroreport	MEDLINE
Carpenter, D	1992	656	668	Ann NY Acad Sci	HCAPLUS
Chieng, B	1994	113	121	Br J Pharmacol	HCAPLUS
Chieng, B	1994	113	303	Br J Pharmacol	HCAPLUS
Coleman, P	1989	61	218	J Neurophysiol	MEDLINE
Dutia, M	1992	88	466	Exp Brain Res	HCAPLUS
Dutia, M	1998	118	148	Exp Brain Res	HCAPLUS
Dutia, M	1996	141	141	Exp Neurol	HCAPLUS
Fallon, J	1986	249	293	J Comp Neurol	HCAPLUS
Finley, J	1981	198	541	J Comp Neurol	HCAPLUS
Grudt, T	1995	6	279	Rev Neurosci	MEDLINE
Johnston, A	1994	481	61	J Physiol (Lond)	HCAPLUS
Johnston, A	1996	219	17	Neurosci Lett	HCAPLUS
Kawabata, A	1990	47	1355	Life Sci	HCAPLUS
Kinney, G	1994	72	1588	J Neurophysiol	HCAPLUS
Kosterlitz, H	1981	73	299	Br J Pharmacol	
Lannou, J	1983		463	Development of the a	
Lin, Y	1994	262	99	Eur J Pharmacol	HCAPLUS
Lu, Y	1995	73	670	Can J Physiol Pharma	HCAPLUS
McFadzean, I	1988	11	173	Neuropeptides	HCAPLUS
Mosberg, H	1983	80	5871	Proc Natl Acad Sci U	HCAPLUS
Nomura, I	1984	311	109	Brain Res	HCAPLUS
Pearson, J	1980	26	1047	Life Sci	HCAPLUS
Saika, T	1993		237	Mol Brain Res	HCAPLUS
Schlosser, B	1995	191	126	Neurosci Lett	MEDLINE
Serafin, M	1991	84	417	Exp Brain Res	MEDLINE
Shippenberg, T	1995	280	55	Eur J Pharmacol	HCAPLUS
Smith, P		16	117	Brain Res Brain Res	HCAPLUS
Smith, P	1989	14	155	Brain Res Brain Res	MEDLINE
Smith, P	1992	17	183	Brain Res Brain Res	HCAPLUS
Suarez-Roca, H	1993	264	648	J Pharmacol Exp Ther	HCAPLUS
Sulaiman, M	1997	504P	166	J Physiol (Lond)	
Travagli, R	1995	74	518	J Neurophysiol	MEDLINE
Vaughan, C	1997	498	463	J Physiol (Lond)	HCAPLUS
Wolozin, B	1981	78	6181	Proc Natl Acad Sci U	HCAPLUS
Zanni, M	1995	36	443	Brain Res Bull	HCAPLUS

L83 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:409124 HCAPLUS
DN 127:75928
TI Segmental effects on motor function following different intrathecal receptor agonists and antagonists in rabbits
AU Borgbjerg, F. M.; Frigast, C.
CS The Pain Clinic, Bispebjerg Hospital, University of Copenhagen, Frederiksberg, Den.
SO Acta Anaesthesiologica Scandinavica (**1997**), 41(5), 586-594
CODEN: AANEAB; ISSN: 0001-5172
PB Munksgaard
DT Journal
LA English
AB The occurrence of motor impairment after intrathecal drug administration is infrequently reported in the literature and the methods of determining motor function vary. Motor function was examined in rabbits after a wide dose range of a variety of intrathecally administered opioid agonists, α-adrenergic agonists, non-competitive NMDA antagonists, a benzodiazepine agonist, a sigma agonist, paracetamol, isotonic and acidified saline. The opioids, sigma agonist and NMDA antagonists were addnl. examined following pretreatment with naloxone. The opioid antagonists naltrindole and MR2266 (δ- and κ-opioid receptor antagonists, resp.) were administered before the δ agonist and the κ agonist. The α2-adrenergic antagonist yohimbine was given before administration of dexmedetomidine and xylazine. Motor function was evaluated by a five-point scale of motor impairment ranging from normal function to total paralysis of the hindlegs. DPDPE (δ agonist), paracetamol, naloxone, naltrindole, yohimbine, isotonic and acidified saline did not affect motor function. MR2266 produced minor motor impairment. The α-adrenergic agonist dexmedetomidine reduced motor function slightly and dose independently. The remaining compds. affected motor function in a dose-dependent fashion. High doses of morphine produced hypersensitivity and myoclonus. An irreversible paralysis of the hindlegs was observed following intrathecal administration of the sigma agonist SKF10047 in high doses. Naloxone and MR2266 attenuated the effects of U50488H (κ agonist). The present results reveal a dose-dependent reduction in motor function after intrathecal administration of some of the investigated compds. The mechanisms behind these effects appear to be multifactorial.
CC 1-11 (Pharmacology)
IT Opioid antagonists
Opioids
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(segmental effects on motor function following different intrathecal receptor agonists and antagonists in rabbits)
IT **57-27-2**, Morphine, biological studies 103-90-2, Paracetamol 146-48-5, Yohimbine 465-65-6, Naloxone 6740-88-1 7361-61-7, Xylazine 14198-28-8, SKF 10047 33643-49-1, (+)-Ketamine 54340-58-8, Meptazinol 56649-76-4, MR 2266 59467-70-8, Midazolam 83913-06-8, U 50488H **88373-73-3 111555-53-4**, Naltrindole 113775-47-6, Dexmedetomidine
RL: **ADV (Adverse effect, including toxicity)**; **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(segmental effects on motor function following different intrathecal receptor agonists and antagonists in rabbits)
IT **57-27-2**, Morphine, biological studies **88373-73-3 111555-53-4**, Naltrindole

RL: **ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(segmental effects on motor function following different intrathecal receptor agonists and antagonists in rabbits)

RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 88373-73-3 HCAPLUS
CN D-Valine, L-tyrosyl-3-mercapto-D-valylglycyl-L-phenylalanyl-3-mercapto-, cyclic (2→5)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Acalovschi, I	1995	81	539	Anesth Analg	HCAPLUS
Bion, J	1984	39	1023	Anaesthesia	MEDLINE
Carter, A	1994	269	573	J Pharmacol Exp Ther	HCAPLUS
Caudle, R	1987	435	1	Brain Res	HCAPLUS
Cousins, M	1988		955	Neural blockade in c	
Crawford, M	1993	70	642	Br J Anaesth	MEDLINE
Drewdy, E	1973	52	839	Anesth Analg	
Faden, A	1983	91	321	Eur J Pharmacol	HCAPLUS
Fernandez-Galinski, S	1996	40	39	Acta Anaesthesiol Sc	HCAPLUS
Fisher, B	1991	192	221	Eur J Pharmacol	HCAPLUS
Glynn, C	1995	64	337	Pain	
Gordh, T	1988	32	702	Acta Anaesthesiol Sc	
Grace, D	1994	73	628	Br J Anaesth	MEDLINE
Groudine, S	1995	82	292	Anesthesiology	MEDLINE
Hertz, A	1970	9	539	Neuropharmacol	
Hill, D	1995	50	415	Anaesthesia	MEDLINE
Jacobson, L	1990	43	141	Pain	MEDLINE
Jensen, F	1988	43	747	Life Sci	HCAPLUS
Klepper, I	1987	59	1147	Br J Anaesth	HCAPLUS
Kristensen, J	1994	56	59	Pain	HCAPLUS
Leblanc, P	1988	193	1405	JAVMA	HCAPLUS
Madsen, J	1993	37	307	Acta Anaesthesiol Sc	MEDLINE
Miaskowski, C	1991	553	105	Brain Res	HCAPLUS
Mollenholt, P	1988	32	95	Pain	HCAPLUS
Nasstrom, J	1992	212	21	Eur J Pharmacol	MEDLINE
Palacios, Q	1991	38	24	Can J Anaesth	MEDLINE
Parkinson, S	1990	72	743	Anesthesiology	MEDLINE
Plummer, J	1992	49	145	Pain	HCAPLUS
Rigoli, M	1983		69	Clinical pharmacolog	
Spampinato, S	1988	35	95	Pain	HCAPLUS
Stevens, C	1986	238	838	J Pharmacol Exp Ther	
Tiseo, P	1993	236	89	Eur J Pharmacol	HCAPLUS
Tung, A	1981	6	91	Reg Anaesth	
Wang, J	1979	50	149	Anesthesiology	MEDLINE
Woolf, C	1981	209	491	Brain Res	HCAPLUS
Yaksh, T	1981	11	293	Pain	HCAPLUS
Yanez, A	1990	29	359	Neuropharmacology	HCAPLUS

L83 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:407072 HCAPLUS
DN 127:104221
TI Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats
AU Hepburn, Matthew J.; Little, Patrick J.; Gingras, Jeanine; Kuhn, Cynthia M.
CS Departments of Pharmacology and Pediatrics, Duke University Medical Center, Durham, NC, 27710, USA
SO Journal of Pharmacology and Experimental Therapeutics (**1997**), 281(3), 1350-1356
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English
AB This study investigated the effect of delta opioid receptor blockade by naltrindole on the development of phys. dependence and tolerance to the antinociceptive and respiratory depressive effects of morphine in rats. Chronic morphine was delivered either by s.c. injection of increasing amts. of morphine over 5 days or by s.c. implantation of morphine pellets. Animals were cotreated with saline or naltrindole. Antinociception and respiratory depression were assessed after administration of a challenge dose or morphine, and withdrawal signs were determined after naloxone challenge. Naltrindole significantly attenuated the development of antinociceptive tolerance after all three chronic treatment regimens. In addition, rats pretreated with naltrindole displayed significantly fewer withdrawal symptoms and less weight loss after a naloxone challenge. In contrast, naltrindole did not prevent the development of tolerance to morphine-induced respiratory depression. These results imply that tolerance to antinociception and phys. dependence involves adaptations at interacting mu and delta receptor populations, whereas tolerance to respiratory depression reflects actions of independent mu and delta receptor populations. These findings suggest that delta antagonists may have potential clin. application for decreasing the rapid development of tolerance to opiate-induced analgesia, while allowing for the development of protective tolerance to respiratory depression.
CC 1-11 (Pharmacology)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonist naltrindole effects on tolerance to opiate-induced analgesia and respiratory depression)
IT **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonist naltrindole effects on tolerance to opiate-induced analgesia and respiratory depression)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonist naltrindole effects on tolerance to opiate-induced analgesia and respiratory depression)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonist naltrindole effects on tolerance to opiate-induced analgesia and respiratory depression)
RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:482971 HCAPLUS
DN 125:185592
TI Evaluation of new compounds for opioid activity (1995)
AU Woods, J. H.; Medzihradsky, F.; Smith, C. B.; Butelman, E. R.; Winger, G.
CS Department Pharmacology, University Michigan, Ann Arbor, MI, USA
SO NIDA Research Monograph (**1996**), 162(Problems of Drug Dependence, 1995), 377-407
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
AB This report contains information on opioid abuse liability evaluations on compds. that have been submitted to the Drug Evaluation Committee of the College and released for publication by the submitters. The information obtained can involve both in vitro evaluation in opioid binding assays and smooth muscle prepns. In addition, the compds. may be evaluated for

discriminative and reinforcing effects. Analgesic and respiratory function assays are also possible. The behavioral assessments are conducted in rhesus monkeys.
CC 1-11 (Pharmacology)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity in relation to abuse liability and analgesic activity and effect on respiratory function)
IT 510-66-7, Metathebainone 1477-40-3 2149-70-4, Nω-Nitro-L-arginine 2183-56-4 34758-83-3, Zipeprol 50903-99-6, Nω-Nitro-L-arginine methyl ester 54934-75-7 55708-52-6 96917-41-8 **111469-88-6**, Oxymorphindole 123931-04-4 131729-08-3 132539-07-2 160039-22-5 173484-64-5 180989-00-8 180989-01-9 180989-03-1 180989-06-4 180989-07-5 180989-08-6 180989-09-7 180989-10-0
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity in relation to abuse liability and analgesic activity and effect on respiratory function)
IT **111469-88-6**, Oxymorphindole
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(evaluation of new compds. for opioid activity in relation to abuse liability and analgesic activity and effect on respiratory function)
RN 111469-88-6 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 5,6,7,8,14,14b-hexahydro-7-methyl-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:670486 HCAPLUS
DN 123:74784
TI Antagonism at delta opioid receptors blocks cocaine's, but not morphine's, enhancement of responding for intracranial stimulation
AU Hubbell, Christopher L.; Reid, Larry D.

CS Laboratory Psychopharmacology, Rensselaer Polytechnic Institute, Troy, NY, 12180-3590, USA
SO Experimental and Clinical Psychopharmacology (**1995**), 3(2), 123-8
CODEN: ECLPES; ISSN: 1064-1297
PB American Psychological Association
DT Journal
LA English
AB Rats were fixed with a chronically indwelling bipolar electrode for direct elec. stimulation of the medial forebrain bundle as it courses through the lateral hypothalamus. In Experiment 1, the rats were trained to self-stimulate (i.e., lever press) at each of 3 intensities of intracranial stimulation (ICS) for 10 min daily. In Experiment 2, only 2 intensities were offered. After stable daily rates of responding for each intensity of ICS were established, rats received either cocaine (5 or 10 mg/kg) or morphine (4 mg/kg) daily. Both cocaine and morphine significantly increased rates of responding. Naltrindole (NTI; 10 mg/kg) reduced rats' rates of responding under cocaine to those observed under vehicle. NTI had very little impact on morphine's effects. These data support the conclusion that selective δ opioid receptor antagonists may be useful for treating cocaine addiction.
CC 1-11 (Pharmacology)
IT 50-36-2, Cocaine **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonists effect on cocaine and morphine enhancement of responding for intracranial stimulation)
IT **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(delta opioid antagonists effect on cocaine and morphine enhancement of responding for intracranial stimulation)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(delta opioid antagonists effect on cocaine and morphine enhancement of responding for intracranial stimulation)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU

(Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(delta opioid antagonists effect on cocaine and morphine enhancement of responding for intracranial stimulation)

RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:259411 HCAPLUS
DN 122:46304
TI The novel and highly selective δ-opioid antagonist TIPP(ψ) attenuates morphine tolerance and dependence: comparison with the effects of naltrindole and TIPP
AU Fundytus, M. E.; Schiller, P. W.; Shapiro, M.; Weltrowska, G.; Coderre, T. J.
CS Pain Mechanisms Chem. biol. Peptide Res. Labs., Clin. Res. Inst. Montreal, Montreal, QC, Can.
SO Regulatory Peptides (**1994**), 54(1), 97-8
CODEN: REPPDY; ISSN: 0167-0115
PB Elsevier
DT Journal
LA English
AB The purpose of the study was to verify the specific involvement of δ-opioid receptors in the development of morphine tolerance and dependence by comparing the effects of naltrindole and the 2 highly selective δ-opioid antagonists, TIPP and TIPP[Ψ], in rats treated chronically with morphine. All 3 δ-opioid antagonists attenuated the severity of precipitated withdrawal symptoms, and TIPP[Ψ], but not naltrindole or TIPP, also attenuated the development of analgesic tolerance. These results suggest that the development of opioid tolerance and dependence may be minimized by combined μ-opioid agonist and δ-opioid antagonist treatment.
CC 1-11 (Pharmacology)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(δ-opioid antagonists attenuation of morphine tolerance and dependence)

IT **111555-53-4**, Naltrindole 146369-65-5 159992-07-1
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(δ-opioid antagonists attenuation of morphine tolerance and dependence)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(δ-opioid antagonists attenuation of morphine tolerance and dependence)
RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(δ-opioid antagonists attenuation of morphine tolerance and dependence)
RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L83 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:672189 HCAPLUS
DN 121:272189
TI Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
IN Portoghese, Philip S.; Takemori, Akira E.
PA Regents of the University of Minnesota, USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5352680	A	19941004	US 1992-914448	19920715 <--
PRAI US 1992-914448		19920715 <--		

OS MARPAT 121:272189
AB A therapeutic method is provided to alleviate the tolerance to, or dependence on, an opiate analgesic (morphine, codeine, etc.) by the administration of an effective amount of a selective δ opioid receptor antagonist (Markush included) to a human patient in need of such treatment. The effect of naltrindole and naltrindole 5'isothiocyanate on μ opioid receptors and on the development of morphine tolerance and dependence in mice chronically treated with morphine are described.
IC ICM A61K0031-485
INCL 514279000
CC 1-11 (Pharmacology)
Section cross-reference(s): 4
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(δ opioid receptor antagonists to block opioid agonist tolerance and dependence)
IT **Opioids**
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(μ-, δ opioid receptor antagonists to block opioid agonist tolerance and dependence)
IT **57-27-2**, Morphine, biological studies 57-42-1, Meperidine 64-31-3, Morphine sulfate 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 77-07-6, Levorphanol 125-29-1, Hydrocodone 143-52-2, Metopon 437-38-7, Fentanyl 466-99-9, Hydromorphone 469-62-5, Propoxyphene 561-27-3, Diacetyl morphine 639-46-3, Morphine-N-oxide 639-47-4, Heterocodeine 915-30-0, Diphenoxylate 1477-40-3, Levacetylmethadol 33522-95-1, Noroxymorphone 41135-98-2 51931-66-9, Tilidine 56030-54-7, Sufentanil 71195-58-9, Alfentanil
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(δ opioid receptor antagonists to block opioid agonist tolerance and dependence)
IT **111555-53-4**, Naltrindole 126876-64-0, Naltrindole 5'-isothiocyanate
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(δ opioid receptor antagonists to block opioid agonist tolerance and dependence)
IT **57-27-2**, Morphine, biological studies
RL: **ADV (Adverse effect, including toxicity)**; BIOL (Biological study)
(δ opioid receptor antagonists to block opioid agonist tolerance and dependence)

RN 57-27-2 HCAPLUS
CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
(5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **111555-53-4**, Naltrindole
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(δ opioid receptor antagonists to block opioid agonist tolerance and dependence)
RN 111555-53-4 HCAPLUS
CN 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol,
7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (4bS,8R,8aS,14bR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



=> => fil medline embase
FILE 'MEDLINE' ENTERED AT 09:05:16 ON 15 JUN 2006

FILE 'EMBASE' ENTERED AT 09:05:16 ON 15 JUN 2006

=> d all tot

L111 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
AN 1999349505 MEDLINE
DN PubMed ID: 10422643
TI Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus

reserved on STN
AN 2003123629 EMBASE
TI Preclinical and clinical studies on naltrexone: What have they taught each other?.
AU Froehlich J.; O'Malley S.; Hyytia P.; Davidson D.; Farren C.
CS Dr. J. Froehlich, Indiana Univ. School of Medicine, IB 424, 975 W. Walnut Street, Indianapolis, IN 46202-5124, United States. jcfroehli@iupui.edu
SO Alcoholism: Clinical and Experimental Research, (1 Mar 2003) Vol. 27, No. 3, pp. 533-539. .
Refs: 36
ISSN: 0145-6008 CODEN: ACRSDM
CY United States
DT Journal; Conference Article
FS 037 Drug Literature Index
038 Adverse Reactions Titles
040 Drug Dependence, Alcohol Abuse and Alcoholism
LA English
SL English
ED Entered STN: 3 Apr 2003
Last Updated on STN: 3 Apr 2003
AB Proceedings of a symposium at the 2002 RSA/ISBRA Meeting in San Francisco, California; organized and co-chaired by Janice C. Froehlich and Stephanie O'Malley. The presentations were (1) Introduction, by Janice C. Froehlich and Stephanie O'Malley; (2) Preclinical studies on naloxone: genetics and site of action, by Petri Hyytia; (3) Clinical studies on naltrexone for treating hazardous drinkers, by Dena Davidson; (4) Clinical studies on naltrexone and sertraline in the treatment of alcohol dependence, by Conor Farren; and (5) Discussion by Janice D. Froehlich, Stephanie O'Malley, and Rainer Spanagel. Both preclinical and clinical studies are critical in the development of effective pharmacotherapeutic approaches for the treatment of alcoholism. Nowhere has this been more evident than in the development of naltrexone for the treatment of alcohol relapse. As research continues on the optimal use of naltrexone for modifying alcohol intake, a number of factors have emerged that are likely to determine the efficacy of naltrexone as a pharmacotherapeutic agent for the treatment of alcoholism. Some of these factors include dose, frequency and duration of treatment, pattern and severity of alcohol drinking prior to initiation of naltrexone treatment, genetic aspects of responsive subpopulations, degree of alcohol craving, and susceptibility to adverse effects of naltrexone. New, as well as established, animal models are being used to determine the parameters that optimize the ability of naltrexone to modify alcohol drinking in acute and chronic alcohol access paradigms, under conditions of intermittent versus continuous alcohol intake, and in populations that vary in genetic predisposition toward alcohol drinking. Current clinical studies are exploring the ability of naltrexone to alter alcohol drinking when delivered in combination with pharmacotherapeutic agents that act on nonopioid transmitter systems and the difference in efficacy of naltrexone when administered in populations that differ in drinking frequency and intensity, family history of alcoholism, and alcohol craving. This symposium presented new research findings from both preclinical and clinical studies with the aim of facilitating the development of treatment regimens that optimize the therapeutic potential of naltrexone in the treatment of alcoholism.
CT Medical Descriptors:
*alcoholism: DT, drug therapy
*alcoholism: TH, therapy
drug efficacy
relapse
drug research

disease severity
genetic predisposition
drug potency
drug effect
dose response
behavior therapy
nausea: SI, side effect
anxiety disorder: SI, side effect
headache: SI, side effect
insomnia: SI, side effect
fatigue: SI, side effect
vertigo: SI, side effect
treatment outcome
drug indication
drug tolerability
abstinence
drug potentiation
human
nonhuman
clinical trial
conference paper
priority journal
Drug Descriptors:
*naltrexone: AE, adverse drug reaction
*naltrexone: CT, clinical trial
*naltrexone: CB, drug combination
*naltrexone: IT, drug interaction
*naltrexone: DT, drug therapy
*naltrexone: PD, pharmacology
*opiate antagonist: AE, adverse drug reaction
*opiate antagonist: CT, clinical trial
*opiate antagonist: CB, drug combination
*opiate antagonist: IT, drug interaction
*opiate antagonist: DT, drug therapy
*opiate antagonist: PD, pharmacology
naloxone: DT, drug therapy
naloxone: PD, pharmacology
naloxone: SC, subcutaneous drug administration
dextro phenylalanylcysteinyltyrosyl dextro tryptophylornithylthreonylpenic illaminylthreoninamide 2,7 disulfide: DO, drug dose
dextro phenylalanylcysteinyltyrosyl dextro tryptophylornithylthreonylpenic illaminylthreoninamide 2,7 disulfide: DT, drug therapy
dextro phenylalanylcysteinyltyrosyl dextro tryptophylornithylthreonylpenic illaminylthreoninamide 2,7 disulfide: PD, pharmacology
dextro phenylalanylcysteinyltyrosyl dextro tryptophylornithylthreonylpenic illaminylthreoninamide 2,7 disulfide: CE, intracerebral drug administration
naltrindole: DO, drug dose
naltrindole: DT, drug therapy
naltrindole: PD, pharmacology
naltrindole: CE, intracerebral drug administration
alcohol
placebo
sertraline: CT, clinical trial
sertraline: IT, drug interaction
sertraline: DT, drug therapy
sertraline: PD, pharmacology
fluoxetine: PD, pharmacology
RN (naltrexone) 16590-41-3, 16676-29-2; (naloxone) 357-08-4, 465-65-6; (dextro phenylalanylcysteinyltyrosyl dextro tryptophylornithylthreonylpeni

cillaminylthreoninamide 2,7 disulfide) 103429-31-8; (**naltrindole**) **111555-53-4**; (alcohol) 64-17-5; (sertraline) 79617-96-2; (fluoxetine) 54910-89-3, 56296-78-7, 59333-67-4

L111 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2002241557 EMBASE
TI Cough: Potential pharmacological developments.
AU Chung K.F.
CS Dr. K.F. Chung, National Heart and Lung Institute, Imperial College, Royal Brompton/Harefield NHS Trust, Dovehouse Street, London SW3 6LY, United Kingdom. f.chung@ic.ac.uk
SO Expert Opinion on Investigational Drugs, (2002) Vol. 11, No. 7, pp. 955-963. .
Refs: 79
ISSN: 1354-3784 CODEN: EOIDER
CY United Kingdom
DT Journal; General Review
FS 011 Otorhinolaryngology
015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 25 Jul 2002
Last Updated on STN: 25 Jul 2002
AB Cough is an important defensive reflex of the upper airway and is also a very common symptom of respiratory disease. Cough following an upper respiratory viral infection is transient, and persistent cough is associated with a whole range of conditions, such as asthma, rhino-sinusitis and gastro-oesophageal reflux. Treatment directed at these conditions may improve the associated cough. There is often a need, however, to control cough itself whatever the cause. The most effective drugs in this class are the opioids, such as morphine, codeine or pholcodeine, but at effective doses they have side effects including drowsiness, **nausea**, constipation and physical dependence. Investigations into the cough reflex and into the potential mechanisms of sensitised cough reflex have uncovered several potential targets for novel drugs. New opioids apart from μ-agonists such as κ- and δ-receptor agonists, have been developed, in addition to non-opioids such as nociceptin. Neurokinin receptor antagonists, bradykinin receptor antagonists, vanniloid receptor VR-1 antagonists may be beneficial by blocking effects of tachykinins and sensory nerve activation. Local anaesthetics, blockers of sodium-dependent channels and maxi-K Ca(2+)-dependent channel activators of afferent nerves are inhibitors of the cough reflex. Some of these novel agents may act centrally or peripherally or at both sites as antitussives. Large scale trials of these novel compounds have not been carried out in cough in man but there is a serious need for more effective antitussives devoid of side effects.
CT Medical Descriptors:
*coughing: DT, drug therapy
*coughing: ET, etiology
symptomatology
respiratory tract disease
upper respiratory tract infection
virus infection
disease association
asthma
rhinosinusitis

gastroesophageal reflux
drug efficacy
dose response
drowsiness: SI, side effect
nausea: SI, side effect
constipation: SI, side effect
drug dependence: SI, side effect
drug targeting
drug mechanism
sensory stimulation
drug antagonism
respiration depression: SI, side effect
diuresis
sedation
human
nonhuman
clinical trial
animal experiment
animal model
controlled study
review

CT Drug Descriptors:
*antitussive agent: AE, adverse drug reaction
*antitussive agent: CT, clinical trial
*antitussive agent: CB, drug combination
*antitussive agent: DV, drug development
*antitussive agent: DO, drug dose
*antitussive agent: IT, drug interaction
*antitussive agent: DT, drug therapy
*antitussive agent: PD, pharmacology
*antitussive agent: IH, inhalational drug administration
*antitussive agent: IA, intraarterial drug administration
*antitussive agent: CV, intracerebroventricular drug administration
*antitussive agent: IV, intravenous drug administration
*antitussive agent: TP, topical drug administration
opiate: AE, adverse drug reaction
opiate: DO, drug dose
opiate: DT, drug therapy
pholcodeine: AE, adverse drug reaction
pholcodeine: DO, drug dose
pholcodeine: DT, drug therapy
morphine: AE, adverse drug reaction
morphine: DO, drug dose
morphine: DT, drug therapy
codeine: AE, adverse drug reaction
codeine: CB, drug combination
codeine: DO, drug dose
codeine: IT, drug interaction
codeine: DT, drug therapy
mu opiate receptor agonist: AE, adverse drug reaction
mu opiate receptor agonist: DV, drug development
mu opiate receptor agonist: DT, drug therapy
mu opiate receptor agonist: PD, pharmacology
mu opiate receptor agonist: TP, topical drug administration
kappa opiate receptor agonist: AE, adverse drug reaction
kappa opiate receptor agonist: DV, drug development
kappa opiate receptor agonist: DT, drug therapy
kappa opiate receptor agonist: PD, pharmacology
delta opiate receptor agonist: AE, adverse drug reaction
delta opiate receptor agonist: DV, drug development

delta opiate receptor agonist: DT, drug therapy
delta opiate receptor agonist: PD, pharmacology
anandamide: PD, pharmacology
nociceptin: AE, adverse drug reaction
nociceptin: DV, drug development
nociceptin: DT, drug therapy
nociceptin: EC, endogenous compound
nociceptin: PD, pharmacology
nociceptin: CV, intracerebroventricular drug administration
nociceptin: IV, intravenous drug administration
tachykinin receptor antagonist: DT, drug therapy
tachykinin receptor antagonist: PD, pharmacology
bradykinin antagonist: DT, drug therapy
bradykinin antagonist: PD, pharmacology
tachykinin: EC, endogenous compound
local anesthetic agent: DT, drug therapy
local anesthetic agent: PD, pharmacology
local anesthetic agent: IH, inhalational drug administration
sodium channel blocking agent: CT, clinical trial
sodium channel blocking agent: DT, drug therapy
sodium channel blocking agent: PD, pharmacology
sodium channel blocking agent: IH, inhalational drug administration
sodium channel blocking agent: IA, intraarterial drug administration
potassium channel stimulating agent: DT, drug therapy
potassium channel stimulating agent: PD, pharmacology
furosemide: DT, drug therapy
furosemide: PD, pharmacology
furosemide: IH, inhalational drug administration
diuretic agent: DT, drug therapy
diuretic agent: PD, pharmacology
diuretic agent: IH, inhalational drug administration
phosphodiesterase IV inhibitor: DT, drug therapy
phosphodiesterase IV inhibitor: PD, pharmacology
corticosteroid: DT, drug therapy
corticosteroid: IH, inhalational drug administration
leukotriene receptor blocking agent: DT, drug therapy
17 methylnalorphine: CB, drug combination
17 methylnalorphine: IT, drug interaction
tyrosyl dextro arginylglycyl 4 nitrophenylalanylprolinamide: DT, drug therapy
tyrosyl dextro arginylglycyl 4 nitrophenylalanylprolinamide: PD, pharmacology
tyrosyl dextro arginylglycyl 4 nitrophenylalanylprolinamide: TP, topical drug administration
naltrindole: DT, drug therapy
naltrindole: PD, pharmacology
resiniferatoxin: CM, drug comparison
resiniferatoxin: DV, drug development
resiniferatoxin: DT, drug therapy
resiniferatoxin: PD, pharmacology
delta opiate receptor antagonist: DV, drug development
delta opiate receptor antagonist: DT, drug therapy
delta opiate receptor antagonist: PD, pharmacology
delta opiate receptor antagonist: PO, oral drug administration
levdropropizine: CM, drug comparison
levdropropizine: DT, drug therapy
levdropropizine: PD, pharmacology
dextromethorphan: CM, drug comparison
dextromethorphan: DT, drug therapy
capsazepine: CM, drug comparison

capsazepine: DV, drug development
capsazepine: DT, drug therapy
capsazepine: PD, pharmacology
unindexed drug
unclassified drug
RN (opiate) 53663-61-9, 8002-76-4, 8008-60-4; (morphine) 52-26-6, 57-27-2; (codeine) 76-57-3; (anandamide) 94421-68-8; (nociceptin) 170713-75-4; (furosemide) 54-31-9; (17 methylnalorphine) 4121-75-9; (tyrosyl dextro arginylglycyl 4 nitrophenylalanylprolinamide) 88331-14-0; (**naltrindole**) **111555-53-4**; (resiniferatoxin) 57444-62-9; (levdropropizine) 99291-24-4; (dextromethorphan) 125-69-9, 125-71-3; (capsazepine) 138977-28-3

L111 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2002296969 EMBASE
TI Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation.
AU Choi Y.S.; Billings J.A.
CS Dr. J.A. Billings, MGH Palliative Care Service, FND 600, 55 Fruit Street, Boston, MA 02114, United States
SO Journal of Pain and Symptom Management, (2002) Vol. 24, No. 1, pp. 71-90.
.
Refs: 207
ISSN: 0885-3924 CODEN: JPSMEU
PUI S 0885-3924(02)00424-4
CY United States
DT Journal; General Review
FS 030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
LA English
SL English
ED Entered STN: 5 Sep 2002
Last Updated on STN: 5 Sep 2002
AB Opioid antagonists have well-established indications in the reversal of life-threatening opioid toxicity, but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-related constipation. We briefly review current understanding of opioid receptors, focusing on their complex role in gastrointestinal physiology. We summarize the pharmacology, conventional indications, and clinical usage of three major groups of opioid antagonists, including a promising new peripherally acting agent, methylnaltrexone, which is not commercially available. We suggest an approach to administering opioid antagonists for reduction of life-threatening opioid toxicity in patients with pain. The literature on opioid-induced constipation and its treatment with opioid-antagonists is reviewed in detail. Finally, other potential uses of opioid antagonists in palliative care are described, especially strategies for reducing such opioid side effects as **nausea** and pruritus and for improving analgesia or reducing tolerance by concomitantly administrating both an opioid agonist and low dosages of an antagonist.
CT Medical Descriptors:
*palliative therapy
drug mechanism
pain: DT, drug therapy
constipation: DT, drug therapy
constipation: SI, side effect
nausea: DT, drug therapy

nausea: SI, side effect
pruritus: DT, drug therapy
pruritus: SI, side effect
analgesia
drug effect
gastrointestinal motility
intestine function
human
nonhuman
review
Drug Descriptors:
*opiate: AE, adverse drug reaction
*opiate: TO, drug toxicity
*opiate: PD, pharmacology
*opiate antagonist: DT, drug therapy
*opiate antagonist: PD, pharmacology
*17 methylnaltrexone: DT, drug therapy
*17 methylnaltrexone: PD, pharmacology
delta opiate receptor: EC, endogenous compound
kappa opiate receptor: EC, endogenous compound
mu opiate receptor: EC, endogenous compound
morphine: DO, drug dose
morphine: PD, pharmacology
morphine: TL, intrathecal drug administration
morphine: SC, subcutaneous drug administration
sufentanil: PD, pharmacology
pethidine: PD, pharmacology
enkephalin[2 dextro alanine 4 methylphenylalanine 5 glycine]: PD, pharmacology
enkephalin[2,5 dextro penicillamine]: PD, pharmacology
enkephalin[2 dextro alanine 5 dextro leucine]: PD, pharmacology
leucine enkephalin[2 dextro serine 6 threonine]: PD, pharmacology
butorphanol: PD, pharmacology
bremazocine: PD, pharmacology
spiradoline: PD, pharmacology
3,4 dichloro n methyl n [2 (1 pyrrolidinyl)cyclohexyl]benzeneacetamide: PD, pharmacology
naloxone: PK, pharmacokinetics
naloxone: PD, pharmacology
naloxone: IM, intramuscular drug administration
naloxone: IV, intravenous drug administration
naloxone: SC, subcutaneous drug administration
naltrexone: PK, pharmacokinetics
naltrexone: PD, pharmacology
naltrexone: PO, oral drug administration
beta funaltrexamine: PD, pharmacology
naloxonazine: PD, pharmacology
naltrindole: PD, pharmacology
naltriben: PD, pharmacology
norbinaltorphimine: PD, pharmacology
fentanyl: PD, pharmacology
pentazocine: PD, pharmacology
nalbuphine: PD, pharmacology
buprenorphine: PD, pharmacology
nalmefene: PK, pharmacokinetics
nalmefene: PD, pharmacology
nalmefene: IM, intramuscular drug administration
nalmefene: IV, intravenous drug administration
nalmefene: PO, oral drug administration
nalmefene: SC, subcutaneous drug administration

unindexed drug
nalorphine
RN (opiate) 53663-61-9, 8002-76-4, 8008-60-4; (17 methylnaltrexone) 83387-25-1; (morphine) 52-26-6, 57-27-2; (sufentanil) 56030-54-7; (pethidine) 28097-96-3, 50-13-5, 57-42-1; (enkephalin[2 dextro alanine 4 methylphenylalanine 5 glycine]) 78123-71-4; (enkephalin[2,5 dextro penicillamine]) 88373-73-3, 88381-29-7; (enkephalin[2 dextro alanine 5 dextro leucine]) 63631-40-3; (leucine enkephalin[2 dextro serine 6 threonine]) 75644-90-5; (butorphanol) 42408-82-2; (bremazocine) 75684-07-0; (spiradoline) 87151-85-7; (3,4 dichloro n methyl n [2 (1 pyrrolidinyl)cyclohexyl]benzeneacetamide) 67198-13-4; (naloxone) 357-08-4, 465-65-6; (naltrexone) 16590-41-3, 16676-29-2; (beta funaltrexamine) 72782-05-9; (naloxonazine) 82824-01-9; (**naltrindole**) **111555-53-4**; (naltriben) 111555-58-9; (norbinaltorphimine) 105618-26-6; (fentanyl) 437-38-7; (pentazocine) 359-83-1, 64024-15-3; (nalbuphine) 20594-83-6, 23277-43-2; (buprenorphine) 52485-79-7, 53152-21-9; (nalmefene) 55096-26-9; (nalorphine) 1041-90-3, 57-29-4, 62-67-9
CN U 50488; Narcan; Lethidrone; Revia; Revex

L111 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 92153592 EMBASE
DN 1992153592
TI The opioid peptides of the amphibian skin.
AU Erspamer V.
CS Inst of Medical Pharmacology III, University 'La Sapienza', Citta Universitaria,00100 Rome, Italy
SO International Journal of Developmental Neuroscience, (1992) Vol. 10, No. 1, pp. 3-30. .
ISSN: 0736-5748 CODEN: IJDND6
CY United Kingdom
DT Journal; General Review
FS 030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 13 Jun 1992
Last Updated on STN: 13 Jun 1992
CT Medical Descriptors:
*amphibia
*peptide analysis
*skin
akinesia: ET, etiology
analgesic activity
blood pressure
cardiovascular response
catalepsy: ET, etiology
dose response
drinking behavior
drug effect
drug withdrawal
frog
headache: SI, side effect
hormone release
human
human experiment
intestine motility
intracerebroventricular drug administration
intramuscular drug administration

intrathecal drug administration
intravenous drug administration
mouse
muscle rigidity: ET, etiology
nausea: SI, side effect
nociception
nonhuman
normal human
plasma renin activity
pulse rate
rabbit
rat
review
seizure: ET, etiology
skin tingling: SI, side effect
stomach acid secretion
subcutaneous drug administration
thermoregulation
urine retention: SI, side effect
vomiting: SI, side effect
Drug Descriptors:
mu opiate receptor
*deltorphin: PD, pharmacology
*deltorphin: DO, drug dose
*deltorphin: CM, drug comparison
*deltorphin: AN, drug analysis
*dermorphin: PD, pharmacology
*dermorphin: PK, pharmacokinetics
*dermorphin: TO, drug toxicity
*dermorphin: DO, drug dose
*dermorphin: CM, drug comparison
*dermorphin: AD, drug administration
*dermorphin: AE, adverse drug reaction
*opiate peptide: EC, endogenous compound
angiotensin: EC, endogenous compound
beta endorphin: CM, drug comparison
bombesin: EC, endogenous compound
bradykinin: EC, endogenous compound
ceruletide: EC, endogenous compound
dynorphin: CM, drug comparison
enkephalin: CM, drug comparison
gastrin: EC, endogenous compound
hypophysis hormone: EC, endogenous compound
kassinin: EC, endogenous compound
litorin: EC, endogenous compound
morphine: CM, drug comparison
naloxone: PD, pharmacology
naltrindole: PD, pharmacology
pentazocine: CM, drug comparison
physalaemin: EC, endogenous compound
piperazinedione: EC, endogenous compound
sauvagine: EC, endogenous compound
somatostatin
RN (deltorphin) 119975-64-3; (dermorphin) 77614-16-5; (angiotensin) 11128-99-7, 1407-47-2; (beta endorphin) 59887-17-1; (bombesin) 31362-50-2; (bradykinin) 58-82-2, 5979-11-3; (ceruletide) 17650-98-5; (dynorphin) 74913-18-1; (gastrin) 9002-76-0; (hypophysis hormone) 85883-81-4; (kassinin) 63968-82-1; (litorin) 55749-97-8; (morphine) 52-26-6, 57-27-2; (naloxone) 357-08-4, 465-65-6; (**naltrindole**) **111555-53-4** ; (pentazocine) 359-83-1, 64024-15-3; (physalaemin) 2507-24-6;

(piperazinedione) 29990-68-9; (sauvagine) 74434-59-6; (somatostatin) 38916-34-6, 51110-01-1

=> d his

(FILE 'HOME' ENTERED AT 07:59:19 ON 15 JUN 2006)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 07:59:48 ON 15 JUN 2006

```
L1            1 S US20060052409/PN OR (US2005-520809# OR WO2003-JP8751 OR JP200
                E TORAY/PA,CS
                E KAWAI/AU
                E KAWAI K/AU
L2          227 S E3,E4
                E KAWAI KOJI/AU
L3          227 S E3-E6
                E KAWAI NAME/AU
L4           22 S E4
                E KOJI/AU
L5            1 S E39
L6            1 S E83
                E SAITO/AU
L7          349 S E3-E6
L8           16 S E49,E50
                E SAITO NAME/AU
L9          133 S E4
                E AKIYOSHI/AU
L10           5 S E129
                E SUZUKI/AU
L11          12 S E3
                E SUZUKI T/AU
L12        3764 S E3-E9
                E SUZUKI TOMOHIKO/AU
L13         145 S E3
                E SUZUKI NAME/AU
L14         228 S E4
                E TOMOHIKO/AU
L15           1 S E9
                E HASEBE/AU
L16          38 S E57
L17         132 S E02
                E HASEBE NAME/AU
                E KO/AU
L18           2 S E3
                E KO H/AU
L19         248 S E3-E17
                E KO NAME/AU
L20          30 S E4
                E SUZUKI TSUTOMU/AU
L21         792 S E3-E5
                E TSUTOMU/AU
L22           2 S E3
L23           2 S E36
                E TSUTOMU S/AU
                SEL RN L1
```

FILE 'REGISTRY' ENTERED AT 08:05:14 ON 15 JUN 2006

```
L24          11 S E1-E11
L25             STR
```

```
L26          50 S L25
L27        1550 S L25 FUL
                SAV L27 GEMBEH520/A
L28             STR L25
L29           1 S L28 SAM SUB=L27
L30          14 S L28 FUL SUB=L27
                SAV L30 GEMBEH520A/A
L31             STR L28
L32          49 S L31 SAM SUB=L27
L33         985 S L31 FUL SUB=L27
                SAV L33 GEMBEH520B/A
L34           9 S L24 NOT L30,L33
L35           2 S L24 NOT L34
L36             STR L28
L37             STR L36
L38           1 S L37 CSS SAM SUB=L30
L39          14 S L37 CSS FUL SUB=L30
                SAV L39 GEMBEH520C/A
L40             STR L37
L41           6 S L40 CSS SAM SUB=L33
L42         208 S L40 CSS FUL SUB=L33
                SAV L42 GEMBEH520D/A
L43         222 S L39,L42

     FILE 'HCAOLD' ENTERED AT 08:39:39 ON 15 JUN 2006
L44           1 S L43
                SEL AN
                EDIT E12 /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 08:40:19 ON 15 JUN 2006
L45           2 S E12
L46           1 S L45 NOT BEYER ?/AU
L47         416 S L43
L48          10 S L47 AND L1-L23
L49           9 S L47 AND TORAY?/PA,CS
L50          17 S L1,L48,L49
                E NAUSEA/CT
                E E3=ALL
                E NAUSEA/CT
                E E3+ALL
L51        1394 S E2
                E E4+ALL
L52        2960 S E2
L53        2889 S E3/BI OR E4/BI
L54        8785 S E7/BI
                E E5+ALL
L55        3139 S E6
L56        4436 S ANTIEMETI? OR ANTINAUSEA? OR ANTI()(EMETI? OR NAUSEA?)
                E NAUSEA
L57        9023 S E3-E14,E16-E21,E24,E31
                E VOMIT/CT
L58        2961 S E4-E6
                E E4+ALL
                E VOMIT
L59       10982 S E3-E19,E22-E27
L60           4 S L47 AND L51-L59
L61           1 S L47 AND (A61P001-08 OR A61P0001-08)/IPC,IC,ICM,ICS,ICA,ICI
L62           4 S L60,L61
L63           1 S L50 AND L62
L64           4 S L62,L63
```

```
L65          16 S L50 NOT L64

     FILE 'REGISTRY' ENTERED AT 08:49:02 ON 15 JUN 2006
L66           1 S MORPHINE/CN
L67          28 S C17H19NO3/MF AND 4766.1.6/RID
L68          27 S L67  AND MORPHIN?
L69          27 S L66,L68

     FILE 'HCAPLUS' ENTERED AT 08:50:16 ON 15 JUN 2006
L70        2789 S L69 (L) ADV/RL
L71          15 S L70 AND L47
L72          11 S L43 (L) (THU OR PAC OR PKT OR DMA OR BAC)/RL AND L71
L73          14 S L64,L72
L74           4 S L71 NOT L73
L75           2 S L74 NOT (2002:466697 OR 2000:68481)/AN
L76          16 S L73,L75
L77          11 S L76 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L78           5 S L76 NOT L77
L79         349 S L47 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L80         204 S L79 AND L43 (L) (THU OR PAC OR PKT OR DMA OR BAC)/RL
                E OPIODS/CT
L81        2461 S E68+OLD,NT (L) ADV/RL
L82          13 S L81 AND L80
L83          19 S L77,L82

     FILE 'REGISTRY' ENTERED AT 08:56:23 ON 15 JUN 2006

     FILE 'HCAPLUS' ENTERED AT 08:56:39 ON 15 JUN 2006
L84           1 S L46 AND L47

     FILE 'HCAOLD' ENTERED AT 08:57:17 ON 15 JUN 2006

     FILE 'HCAPLUS' ENTERED AT 08:57:30 ON 15 JUN 2006
L85          19 S L83 NOT L84

     FILE 'MEDLINE' ENTERED AT 08:58:14 ON 15 JUN 2006
L86         530 S L43
L87        1045 S NALTRINDOL?
L88           6 S METHYLNALTRINDOL?
L89        1056 S ?NALTRINDOL?
L90        1061 S L86-L89
                E NAUSEA/CT
                E E3+ALL
L91       10916 S E5+NT
                E VOMIT/CT
                E E4+ALL
L92       18854 S E5+NT
                E E14+ALL
L93         596 S E21
                E ANTIEMETIC/CT
                E E6+ALL
L94        5102 S E17
L95           1 S L90 AND L91-L94
L96           2 S L90 AND (?NAUSE? OR ?VOMIT? OR ?EMETI?)
L97           1 S L96 AND PY<=2003
L98           1 S L95,L97

     FILE 'EMBASE' ENTERED AT 09:01:57 ON 15 JUN 2006
L99        1239 S L43
L100       1339 S L87-L89
```

```
L101        1344 S L99,L100
                 E NAUSEA/CT
L102       92050 S E3+NT OR E4+NT
                 E VOMIT/CT
L103       55342 S E10+NT
L104          19 S E13
                 E ANTINAUSEA/CT
                 E ANTI-NAUSEA/CT
                 E ANTIVOMIT/CT
                 E ANTIEMET/CT
                 E E5+ALL
L105         778 S E1
L106        5950 S E6
L107           9 S L101 AND L102-L106
L108           9 S L101 AND (?NAUSE? OR ?VOMIT? OR ?EMETI?)
L109           9 S L107,L108
L110           5 S L109 AND PY<=2003

     FILE 'MEDLINE, EMBASE' ENTERED AT 09:05:10 ON 15 JUN 2006
L111           5 DUP REM L98 L110 (1 DUPLICATE REMOVED)

     FILE 'MEDLINE, EMBASE' ENTERED AT 09:05:16 ON 15 JUN 2006

=>
```